

BEST AVAILABLE COPY

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 211/22, A61K 31/445, C07D 401/06		A1	(11) International Publication Number: WO 95/19344 (43) International Publication Date: 20 July 1995 (20.07.95)
(21) International Application Number: PCT/GB95/00057			(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).
(22) International Filing Date: 12 January 1995 (12.01.95)			
(30) Priority Data: 9400542.8 13 January 1994 (13.01.94) GB 9403072.3 17 February 1994 (17.02.94) GB			
(71) Applicant (for all designated States except US): MERCK SHARP & DOHME LIMITED [GB/GB]; Hertford Road, Hoddesdon, Hertfordshire EN11 9BU (GB).			Published With international search report.
(72) Inventors; and			
(75) Inventors/Applicants (for US only): BAKER, Raymond [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). LEWIS, Richard, Thomas [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). MACLEOD, Angus, Murray [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). STEVENSON, Graeme, Irvine [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).			
(74) Agent: HISCOCK, Ian, James; Merck & Co., Inc., Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).			

(54) Title: GEM-DISUBSTITUTED AZACYCLIC TACHYKININ ANTAGONISTS



(57) Abstract

The present invention relates to compounds of formula (I), wherein A¹ and A² each independently represent hydrogen or C₁₋₄alkyl; m is 2, 3 or 4; n is zero, 1 or 2 when m is 2 or 3 and n is zero or 1 when m is 4; R¹ represents optionally substituted phenyl; R² represents phenyl; heteroaryl; benzhydryl; or benzyl; each of which may be substituted; R³ represents H, COR⁹, COCONR¹⁰R¹¹, COCO₂R¹⁰, SO₂R¹⁵, CONR¹⁰SO₂R¹⁵, optionally substituted C₁₋₆alkyl, Y-R⁸ or CO-Z-(CH₂)_q-R¹²; R⁴ represents C₁₋₆alkyl substituted by a hydroxy group, or (CH₂)_pNR¹⁰R¹¹, CO₂R¹⁶, CONR¹⁰R¹¹, (CH₂)_pCO₂R¹⁶, (CH₂)_pCONR¹⁰R¹¹, (CH₂)_pNR¹⁰COR¹⁸, (CH₂)_pNR¹⁰SO₂R¹⁵, (CH₂)_pOR¹⁶, (CH₂)_pOC(O)R¹⁰ or (CH₂)_pO(CH₂)_rCOR¹⁷; R⁵ represents hydrogen or C₁₋₆alkyl or any of the substituents defined for R⁴; or R⁴ and R⁵ together with the carbon atom to which they are attached form an optionally substituted C₃₋₆cycloalkyl ring; R⁶ and R⁷ each independently represent H or C₁₋₆alkyl; X represents O or NR₁₉ where R₁₉ represents hydrogen or C₁₋₆alkyl; and pharmaceutically acceptable salts and prodrugs thereof. The compounds are tachykinin antagonists and are of particular use in the treatment of pain, inflammation, migraine and emesis.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

1
GEM-DISUBSTITUTED AZACYCLIC TACHYKININ ANTAGONISTS

5 This invention relates to a class of azacyclic compounds, which are useful as tachykinin antagonists. More particularly, the compounds of the invention comprise an azacyclic ring system substituted by an arylmethoxy or arylmethylthio moiety.

10 The tachykinins are a group of naturally occurring peptides found widely distributed throughout mammalian tissues, both within the central nervous system and in peripheral nervous and circulatory systems.

15 The tachykinins are distinguished by a conserved carboxyl-terminal sequence:

Phe-X-Gly-Leu-Met-NH₂

20 At present, there are three known mammalian tachykinins referred to as substance P, neurokinin A (NKA, substance K, neuromedin L) and neurokinin B (NKB, neuromedin K) (for review see J.E. Maggio, *Peptides* (1985) 6(suppl. 3), 237-242). The current nomenclature designates the three tachykinin receptors mediating the biological actions of substance P, NKA and NKB as the NK₁, NK₂ and NK₃ receptors, respectively.

25 Evidence for the usefulness of tachykinin receptor antagonists in pain, headache, especially migraine, Alzheimer's disease, multiple sclerosis, attenuation of morphine withdrawal, cardiovascular changes, oedema, such as oedema caused by thermal injury, chronic inflammatory diseases such as rheumatoid arthritis, asthma/bronchial hyperreactivity and other respiratory diseases including allergic rhinitis, inflammatory diseases of the gut including ulcerative colitis and Crohn's disease, ocular injury and ocular inflammatory diseases, proliferative vitreoretinopathy, irritable bowel syndrome and disorders of bladder function including cystitis and bladder detrusor hyperreflexia is reviewed in "Tachykinin Receptors and Tachykinin Receptor

Antagonists", C.A. Maggi, R. Patacchini, P. Rovero and A. Giachetti, *J. Auton. Pharmacol.* (1993) 13, 23-93.

For instance, substance P is believed inter alia to be involved in the neurotransmission of pain sensations [Otsuka *et al*, "Role of Substance P as a Sensory Transmitter in Spinal Cord and Sympathetic Ganglia" in 1982 *Substance P in the Nervous System*, Ciba Foundation Symposium 91, 13-34 (published by Pitman) and Otsuka and Yanagisawa, "Does Substance P Act as a Pain Transmitter?" *TIPS* (1987) 8, 506-510], specifically in the transmission of pain in migraine (B.E.B. Sandberg *et al*, *J. Med Chem.* (1982) 25, 1009) and in arthritis [Levine *et al* *Science* (1984) 226, 547-549].

Tachykinins have also been implicated in gastrointestinal (GI) disorders and diseases of the GI tract such as inflammatory bowel disease [Mantyh *et al* *Neuroscience* (1988) 25(3), 817-37 and D. Regoli in "*Trends in Cluster Headache*" Ed. Sicuteli *et al* Elsevier Scientific Publishers, Amsterdam (1987) page 85)] and emesis [F. D. Tattersall *et al*, *Eur. J. Pharmacol.*, (1993) 250, R5-R6]. It is also hypothesised that there is a neurogenic mechanism for arthritis in which substance P may play a role [Kidd *et al* "A Neurogenic Mechanism for Symmetrical Arthritis" in *The Lancet*, 11 November 1989 and Grönblad *et al*, "Neuropeptides in Synovium of Patients with Rheumatoid Arthritis and Osteoarthritis" in *J. Rheumatol.* (1988) 15(12), 1807-10]. Therefore, substance P is believed to be involved in the inflammatory response in diseases such as rheumatoid arthritis and osteoarthritis, and fibrositis [O'Byrne *et al*, *Arthritis and Rheumatism* (1990) 33, 1023-8]. Other disease areas where tachykinin antagonists are believed to be useful are allergic conditions [Hamelet *et al*, *Can. J. Pharmacol. Physiol.* (1988) 66, 1361-7], immunoregulation [Lotz *et al*, *Science* (1988) 241, 1218-21 and Kimball *et al*, *J. Immunol.* (1988) 141(10), 3564-9] vasodilation, bronchospasm, reflex or neuronal control of the viscera [Mantyh *et al*, *PNAS* (1988) 85, 3235-9] and, possibly by arresting or slowing

β -amyloid-mediated neurodegenerative changes [Yankner et al, *Science* (1990) 250, 279-82] in senile dementia of the Alzheimer type, Alzheimer's disease and Down's Syndrome.

5 Tachykinin antagonists may also be useful in the treatment of small cell carcinomas, in particular small cell lung cancer (SCLC) [Langdon et al, *Cancer Research* (1992) 52, 4554-7].


10 Substance P may also play a role in demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis [J. Luber-Narod et al, poster *C.I.N.P. XVIIIth Congress*, 28th June-2nd July 1992], and in disorders 15 of bladder function such as bladder detrusor hyper-reflexia (*Lancet*, 16th May 1992, 1239).

15 It has furthermore been suggested that tachykinins have utility in the following disorders: depression, dysthymic disorders, chronic obstructive airways disease, hypersensitivity disorders such as poison ivy, vasospastic diseases such as angina and Reynaud's disease, fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis, reflex sympathetic dystrophy such as shoulder/hand syndrome, addiction disorders such as alcoholism, stress related somatic disorders, neuropathy, neuralgia, disorders related to immune enhancement or suppression such as systemic 20 lupus erythematosus (European patent specification no. 0 436 334), ophthalmic disease such as conjunctivitis, vernal conjunctivitis, and the like, and cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis (European patent specification no. 0 394 989).

25 In view of their metabolic instability, peptide derivatives are likely to be of limited utility as therapeutic agents. It is for this reason that non-peptide tachykinin antagonists are sought.

In essence, this invention provides a class of potent non-peptide tachykinin antagonists.

The present invention provides a compound of the formula (I) or a pharmaceutically acceptable salt thereof:



wherein

A¹ and A² each independently represent hydrogen or C₁-4alkyl;

m is 2, 3 or 4;

n is zero, 1 or 2 when m is 2 or 3 and n is zero or 1 when m is 4;

R¹ represents phenyl optionally substituted by 1, 2 or 3 groups selected from C₁-6alkyl, C₂-6alkenyl, C₂-6alkynyl, C₃-6cycloalkyl, C₃-6cycloalkylC₁-4alkyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, -OR^a, -SRA^a, -SOR^a, -SO₂R^a, -NR^aR^b, -NR^aCORB, -NR^aCO₂R^b, -CORA, -CO₂R^a or -CONR^aR^b, where R^a and R^b each independently represent H, C₁-6alkyl, phenyl or trifluoromethyl;

R² represents phenyl optionally substituted by 1, 2 or 3 groups selected from C₁-6alkyl, C₂-6alkenyl, C₂-6alkynyl, C₃-6cycloalkyl, C₃-6cycloalkylC₁-4alkyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, -OR^a, -SRA^a, -SOR^a, -SO₂R^a, -NR^aR^b, -NR^aCORB, -NR^aCO₂R^b, -CO₂R^a or -CONR^aR^b, where R^a and R^b are as previously defined; heteroaryl selected from indazolyl, thienyl, furyl, pyridyl, thiazolyl, tetrazolyl and quinolyl; benzhydryl; or benzyl; wherein each heteroaryl and each phenyl moiety of benzyl and benzhydryl may be substituted by C₁-6alkyl, C₃-6cycloalkyl, C₃-6cycloalkylC₁-4alkyl, C₁-6alkoxy, halo or trifluoromethyl;

R³ represents H, COR⁹, CO₂R¹⁰, COCONR¹⁰R¹¹, COCO₂R¹⁰, SO₂R¹⁵, CONR¹⁰SO₂R¹⁵, C₁₋₆alkyl optionally substituted by a group selected from (CO₂R¹⁰, CONR¹⁰R¹¹, hydroxy, cyano, COR⁹, NR¹⁰R¹¹, C(NOH)NR¹⁰R¹¹, CONHphenyl(C₁₋₄alkyl), COCO₂R¹⁰, COCONR¹⁰R¹¹, SO₂R¹⁵, CONR¹⁰SO₂R¹⁵ and phenyl optionally substituted by 1, 2 or 3 substituents selected from C₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₄alkyl, C₁₋₆alkoxy, halo and trifluoromethyl), Y-R⁸ or CO-Z-(CH₂)_q-R¹²;

R⁴ represents C₁₋₆alkyl substituted by a hydroxy group, or (CH₂)_pNR¹⁰R¹¹, CO₂R¹⁶, CONR¹⁰R¹¹, (CH₂)_pCO₂R¹⁶, (CH₂)_pCONR¹⁰R¹¹, (CH₂)_pNR¹⁰COR¹⁸, (CH₂)_pNR¹⁰SO₂R¹⁵, (CH₂)_pOR¹⁶, (CH₂)_pOC(O)R¹⁰ or (CH₂)_pO(CH₂)_rCOR¹⁷;

R⁵ represents hydrogen or C₁₋₆alkyl optionally substituted by a hydroxy group, or (CH₂)_pNR¹⁰R¹¹, CO₂R¹⁶, CONR¹⁰R¹¹, (CH₂)_pCO₂R¹⁶, (CH₂)_pCONR¹⁰R¹¹, (CH₂)_pNR¹⁰COR¹⁸, (CH₂)_pNR¹⁰SO₂R¹⁵, (CH₂)_pOR¹⁶, (CH₂)_pOC(O)R¹⁰ or (CH₂)_pO(CH₂)_rCOR¹⁷;

or R⁴ and R⁵ together with the carbon atom to which they are attached form a C₃₋₆cycloalkyl ring which may be substituted by 1 or 2 groups selected from C₁₋₆alkyl, C₁₋₆alkoxy, hydroxy or C₁₋₆alkyl substituted by hydroxy;

R⁶ and R⁷ each independently represent H or C₁₋₆alkyl;

R⁸ represents an optionally substituted aromatic heterocycle;

R⁹ represents H, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₄alkyl, or phenyl;

R¹⁰ and R¹¹ each independently represent H or C₁₋₆alkyl;

R¹² represents NR¹³R¹⁴ or an optionally substituted aromatic or non-aromatic azacyclic or azabicyclic group;

R¹³ and R¹⁴ each independently represent H, C₁₋₆alkyl, phenyl optionally substituted by 1, 2 or 3 groups selected from C₁₋₆alkyl, C₁₋₆alkoxy, halo or trifluoromethyl, or phenylC₁₋₄alkyl optionally substituted in the phenyl ring by 1, 2 or 3 groups selected from C₁₋₆alkyl, C₁₋₆alkoxy, halo or trifluoromethyl;

R¹⁵ represents C₁₋₆alkyl, trifluoromethyl or phenyl optionally substituted by 1, 2 or 3 substituents selected from C₁₋₆alkyl, C₁₋₆alkoxy, halo and trifluoromethyl;

R¹⁶ represents C₁₋₆alkyl;

R¹⁷ represents C₁₋₆alkoxy, amino, C₁₋₄alkylamino or di(C₁₋₄alkyl)amino;

R¹⁸ represents C₁₋₆alkyl, NR¹³R¹⁴ or an optionally substituted aromatic or non-aromatic azacyclic or azabicyclic group;

X represents O or NR¹⁹ where R¹⁹ represents hydrogen or C₁₋₆alkyl;

Y represents a hydrocarbon chain of 1, 2, 3 or 4 carbon atoms which may optionally be substituted by oxo;

Z represents CH₂, O, S or NR¹⁰;

p represents an integer from 1 to 4;

q represents zero or an integer from 1 to 6; and

r represents an integer from 1 to 4.

As used herein, the definition of each expression, when it occurs more than once in any structure, is intended to be independent of its definition elsewhere in the same structure.

The alkyl, alkenyl and alkynyl groups referred to with respect to the formulae herein may represent straight, branched or cyclic groups, or combinations thereof. Thus, for example, suitable alkyl groups include methyl, ethyl, n- or iso-propyl, n-, sec-, iso- or tert-butyl.

The cycloalkyl groups referred to with respect to the above formula may represent, for example, cyclopropyl, cyclobutyl, cyclopentyl or

cyclohexyl. Similarly, cycloalkyl-alkyl groups may be, for example, cyclopropylmethyl.

Suitable alkenyl groups include vinyl and allyl; and suitable alkynyl groups include propargyl.

The term "halo" as used herein includes fluoro, chloro, bromo and iodo, especially chloro and fluoro.

Those compounds according to the invention which contain one or more chiral centres may exist both as enantiomers and as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.

A^1 and A^2 which may be attached to any carbon atom or atoms in the ring, are aptly hydrogen or methyl and are preferably both hydrogen.

Preferably m is 2.

When m is 2, n is preferably 2. When m is 3 or 4, n is preferably zero.

Preferably R^1 represents substituted phenyl. When R^1 is substituted phenyl suitable substituents include nitro, trifluoromethyl, trimethylsilyl, bromo, chloro, fluoro, iodo, cyano, methyl, ethyl, cyclopropyl, t-butyl, vinyl, methoxy, phenoxy, amino and carbonylmethoxy. Preferably R^1 represents phenyl substituted by 1, 2 or 3 groups selected from C_{1-6} alkyl such as methyl and t-butyl, halo such as chloro, fluoro and bromo, and trifluoromethyl.

Preferably R^1 represents disubstituted phenyl, in particular 3,5-disubstituted phenyl, for example 3,5-disubstituted phenyl wherein the substituents are selected from C_{1-6} alkyl, halo and trifluoromethyl. More preferably R^1 represents 3,5-bis(trifluoromethyl)phenyl. Also preferred are those compounds wherein R^1 represents 3-fluoro-5-(trifluoromethyl)phenyl.

Suitable values for the group R^2 include unsubstituted or substituted phenyl, 5-membered heteroaryl such as thienyl, 6-membered heteroaryl such as pyridyl, and benzhydryl.

Preferably R^2 represents unsubstituted or substituted phenyl.

When R² represents substituted phenyl a preferred substituent is halo, especially fluoro.

When R⁴ represents C₁₋₆alkyl substituted by a hydroxy group, this may be, for example, CH₂OH, CH₂CH₂OH, CH(OH)CH₃ or C(OH)(CH₃)₂, especially CH₂OH.

Preferably R⁴ is C₁₋₆alkyl substituted by hydroxy, or (CH₂)_pNR¹⁰R¹¹, (CH₂)_pCONR⁹R¹⁰, CO₂R¹⁶, (CH₂)_pNR¹⁰COR¹⁸, (CH₂)_pNR¹⁰SO₂R¹⁵, (CH₂)_pOR¹⁶, (CH₂)_pOC(O)R¹⁶ or (CH₂)_pO(CH₂)_rCOR¹⁷, or R⁴ together with R⁵ and the carbon atom to which they are attached forms a C₃₋₆cycloalkyl ring.

When R⁵ represents C₁₋₆alkyl optionally substituted by a hydroxy group, this may be, for example, methyl or hydroxymethyl.

When R⁴ and R⁵ together with the carbon atom to which they are attached form a C₃₋₆cycloalkyl ring, this may be for example, cyclopropyl, cyclobutyl or cyclopentyl, especially cyclopropyl.

When R⁸ represents a substituted aromatic heterocycle, suitable substituents in the heterocyclic ring include 1, 2 or 3 groups selected from C₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₄alkyl, C₁₋₆alkoxy, phenyl, oxo, thioxo, halo, trifluoromethyl, NR^aR^b, NR^aCOR^b, CONR^aR^b, CO₂R^a, SR^a, SO₂R^a and CH₂OR^a, where R^a and R^b are as previously defined.

Particular examples of suitable substituents include methyl, methoxy, phenyl, oxo, thioxo, bromo, iodo, NH₂, SCH₃, CONH₂ and cyano. Particularly preferred substituents include oxo and NH₂.

Suitable values for R⁸ include thienyl, furyl, pyrrolyl, pyridyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, oxazolyl, oxadiazolyl, thiadiazolyl, isoxazolyl, quinolyl, isothiazolyl, imidazolyl, benzimidazolyl, benzoxazolyl, benzothiophenyl, benzofuranyl and indolyl, any of which may be substituted.

Preferably R⁸ represents a substituted or unsubstituted 5- or 6-membered nitrogen containing aromatic heterocycle such as for example oxazolyl, oxadiazolyl, tetrazolyl, thiazolyl, thiadiazolyl, triazolyl, pyrazinyl, pyridyl, pyrimidinyl, pyridazinyl, imidazolyl or triazinyl. More preferably R⁸ represents optionally substituted oxazolyl, oxadiazolyl, imidazolyl, thiadiazolyl, triazolyl, pyrazinyl, pyrimidinyl, pyridazinyl or triazinyl, or tetrazolyl substituted by C₁-6alkyl, preferably methyl.

Also preferred are those compounds in which R⁸ represents an optionally substituted triazolyl group, particularly a triazolinone group.

It will be appreciated that, when the heterocyclic moiety R⁸ is substituted by an oxo or thioxo substituent, different tautomeric forms are possible so that the substituent may be represented as =O or -OH, or =S or -SH, respectively. For the avoidance of doubt, all such tautomeric forms are embraced by the present invention.

When R¹² represents NR¹³R¹⁴, R¹³ and R¹⁴ are preferably both C₁-6alkyl such as methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl or t-butyl. More preferably R¹³ and R¹⁴ will both represent methyl.

When R¹² represents an aromatic or non-aromatic azacycle or azabicycle it may contain 1, 2 or 3 additional heteroatoms selected from O, S and N or groups NR¹⁶, where R¹⁶ is H, C₁-6alkyl or phenylC₁-4alkyl, and may be unsubstituted or substituted. Suitable substituents include C₁-6alkyl, C₃-6cycloalkyl, C₃-6cycloalkylC₁-4alkyl, C₁-6alkoxy, oxo, SH, =S, halo, trifluoromethyl, NR^aR^b, NR^aCOR^b, CONR^aR^b, CO₂R^a and CH₂OR^a, where R^a and R^b are as previously defined.

When R¹² represents an aromatic azacycle or azabicycle, suitable values of R¹² include imidazolyl, triazolyl, tetrazolyl, oxazolyl, thiazolyl, pyrrolyl, pyrazolyl, pyrazinyl, pyridyl, oxadiazolyl, thiadiazolyl, isoxazolyl, isothiazolyl, benzimidazolyl, benzoxazolyl and indolyl, preferably imidazolyl,

such as 2,4-imidazolyl, or pyridyl, more preferably pyridyl such as 4-, 3- or 2-pyridyl.

When R¹² represents a non-aromatic azacycle or azabicycle, suitable values of R¹² include morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, methylpiperazinyl, azanorbornanyl, azabicyclo[2.2.2]octanyl and azabicyclo[3.2.2]nonyl, preferably morpholinyl, pyrrolidinyl, methylpiperazinyl, quinuclidinyl (azabicyclo[2.2.2] octanyl) or azabicyclo[3.2.2]nonyl, more preferably pyrrolidinyl.

Suitably Y represents a hydrocarbon chain of 1 or 2 carbon atoms optionally substituted by oxo, such as CH₂, C=O, CH(CH₃), CH₂CO or COCH₂. Preferably Y represents CH₂, CH(CH₃) or CH₂CO, more preferably CH₂ or CH(CH₃).

Suitably q represents zero, 1, 2 or 3.

Suitable values of R³ include H, COR⁹ such as COCH₃, SO₂R¹⁵ such as SO₂CH₃, C₁₋₆alkyl such as CH₃, CH(CH₃)₂, CH₂CH(CH₃)₂ and CH₂CH₂C(CH₃)₃, C₁₋₆alkyl substituted by CO₂R¹⁰ such as CH₂CO₂CH₃, CH₂CO₂H, (CH₂)₃CO₂CH₃ and (CH₂)₃CO₂H, C₁₋₆alkyl substituted by CONR¹⁰SO₂R¹⁵ such as CH₂CONHSO₂CH₃ and CH₂CONHSO₂C₆H₅, C₁₋₆alkyl substituted by phenyl, Y-R⁸ and CO-Z-(CH₂)_q-R¹².

In one preferred sub-group of compounds according to the invention R⁵ represents H; and most aptly R⁶ and R⁷ also both represent H.

In one preferred sub-group of compounds according to the invention, R³ represents H or C₁₋₆alkyl, more preferably H.

In a further preferred sub-group of compounds according to the invention R³ represents Y-R⁸.


A yet further preferred sub-group of compounds according to the invention is represented by compounds wherein R³ is CO-Z-(CH₂)_q-R¹².

A particularly suitable group R⁴ is the CH₂OH group.

In a further preferred sub-group of compounds of the formula (I), X represents O.

In a further preferred sub-group of compounds of the formula (I), X represents NR¹⁹ wherein R¹⁹ is hydrogen or methyl and is preferably hydrogen.

A particularly suitable sub-class of compounds of the formula (I) are those of formula (Ia) and salts thereof:



10

wherein

R³ and X are as defined for formula (I);

R²⁰ and R²¹ independently represent H, C₁-6alkyl, C₂-6alkenyl, C₂-6alkynyl, C₃-6cycloalkyl, C₃-6cycloalkylC₁-4alkyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a, SR^a, SOR^a, SO₂R^a, NR^aR^b, NR^aCOR^b, NR^aCO₂R^b, COR^a, CO₂R^a or CONR^aR^b, where R^a and R^b are as previously defined;

R²² represents H or halo, preferably H or fluoro; and

R²³ is C₁-6alkyl substituted by a hydroxy group, preferably CH₂OH.

R²⁴ is H or methyl.

Most aptly p is 1.

Most aptly X is O or NH.

Specific compounds within the scope of the invention include:

4-phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)methyl)piperidine;

4-phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-2-methoxyethoxy)methyl)piperidine;

5 4-phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-2-ethoxyethoxy)methyl)piperidine;

4-phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-2-cyclopropylmethoxyethoxy)methyl)piperidine;

10 4-phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-2-methoxycarbonylmethoxyethoxy)methyl)piperidine;

4-phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-2-acetoxyethoxy)methyl)piperidine;

15 5[(4-phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)methyl)piperidin-1-yl)methyl]-2,4-dihydro-[1,2,4]-triazol-3-one;

4-phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)methyl)-1-(2-(1-pyrrolidinyl)acetamido)piperidine;

20 methyl 2-(4-phenylpiperidin-4-yl)methoxy-2-(3,5-bis(trifluoromethyl)phenyl)acetate;

isopropyl 2-(4-phenylpiperidin-4-yl)methoxy-2-(3,5-bis(trifluoromethyl)phenyl)acetate;

25 4-phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropyloxy)methyl)piperidine;

2-(4-phenylpiperidin-4-yl)methoxy-2-(3,5-bis(trifluoromethyl)phenyl)acetamide;

4-phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-aminoethoxy)methyl]piperidine;

4-phenyl-4-[(1-(3-fluoro-5-trifluoromethylphenyl)-2-hydroxyethoxy)methyl]piperidine;

5-[4-phenyl-4-[(1-(3-fluoro-5-trifluoromethylphenyl)-2-hydroxyethoxy)methyl]piperidin-1-ylmethyl]-2,4-dihydro-[1,2,4]-triazol-3-one;

4-phenyl-4-[(1-(3-fluoro-5-trifluoromethylphenyl)-2-hydroxyethoxy)methyl]-1-(2-(pyrrolidinyl)acetamido)piperidine;

5 and pharmaceutically acceptable acid addition salts thereof.

Further preferred compounds within the scope of the present invention include:

4-phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-(3-methylureido)ethoxy)methyl]piperidine;

10 4-phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-acetamido)methyl]piperidine; 4-phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-methansulphonamido)methyl]piperidine;

4-phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-(carbomethoxymethoxy)ethoxy)methyl]piperidine;

15 4-(4-fluorophenyl)-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)methyl]-1-(2-(1-pyrrolidinyl)acetamido)piperidine; (+)-4-(4-fluorophenyl)-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)methyl]-1-(2-(1-pyrrolidinyl)acetamido)piperidine;

4-phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-1-hydroxymethyl-2-hydroxyethoxy)methyl]piperidine;

20 5-[(4-phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-1-hydroxymethyl-2-hydroxyethoxy)methyl)piperidin-1-ylmethyl]-2,4-dihydro-[1,2,4]-triazol-3-one;

4-phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)cyclopropoxy)methyl]piperidine;

25 4-phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)cyclopropoxy)methyl]-1-(2-(1-pyrrolidinyl)acetamido)piperidine;

4-phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-1-methyl-2-hydroxyethoxy)methyl]piperidine;

5-[4-phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-1-methyl-2-hydroxyethoxy)methyl]piperidin-1-yl)methyl]-2,4-dihydro-[1,2,4]-triazol-3-one; and pharmaceutically acceptable acid addition salts thereof.

For use in medicine, the salts of the compounds of formula (I) will be pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention (such as the dibenzoyltartrate salts) or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable non-toxic acid such as hydrochloric acid, sulphuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid or p-toluenesulphonic acid. Salts of amine groups may also comprise quaternary ammonium salts in which the amino nitrogen atom carries a suitable organic group such as an alkyl, alkenyl, alkynyl or aralkyl moiety. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include metal salts such as alkali metal salts, e.g. sodium or potassium salts; and alkaline earth metal salts, e.g. calcium or magnesium salts.

Preferred salts of the compounds according to the invention include the hydrochloride and p-toluenesulphonic acid salts.

The invention also provides pharmaceutical compositions comprising one or more compounds of this invention in association with a pharmaceutically acceptable carrier. Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, solutions or suspensions, or suppositories, for oral, parenteral or rectal administration, or topical administration including administration by inhalation or insufflation.

The invention further provides a process for the preparation of a pharmaceutical composition comprising a compound of formula (I), or a salt thereof, and a pharmaceutically acceptable carrier, which process comprises bringing a compound of formula (I), or a salt thereof into association with a pharmaceutically acceptable carrier or excipient.

For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a non-toxic pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.

Preferred compositions for administration by injection include those comprising a compound of formula (I), as the active ingredient, in association with a surface-active agent (or wetting agent or surfactant) or in the form of an emulsion (as a water-in-oil or oil-in-water emulsion).

Suitable surface-active agents include anionic agents such as sodium bis-(2-ethylhexyl)sulfosuccinate (docusate sodium), cationic agents, such as alkyltrimethylammonium bromides, (e.g. cetyltrimethylammonium bromide (cetrimide)), and in particular, non-ionic agents, such as polyoxyethylenesorbitans (e.g. Tween™ 20, 40, 60, 80 or 85) and other sorbitans (e.g. Span™ 20, 40, 60, 80 or 85). Compositions with a surface-active agent will conveniently comprise between 0.05 and 5% surface-active agent, and preferably between 0.1 and 2.5%. It will be appreciated that other ingredients may be added, for example mannitol or other pharmaceutically acceptable vehicles, if necessary.

Suitable emulsions may be prepared using commercially available fat emulsions, such as Intralipid™, Liposyn™, Infonutrol™, Lipofundin™ and Lipiphysan™. The active ingredient may be either dissolved in a pre-mixed emulsion composition or alternatively it may be dissolved in an oil (e.g. soybean oil, safflower oil, cottonseed oil, sesame oil, corn oil or almond oil) and an emulsion formed upon mixing with a phospholipid (e.g. egg

phospholipids, soybean phospholipids or soybean lecithin) and water. It will be appreciated that other ingredients may be added, for example glycerol or glucose, to adjust the tonicity of the emulsion. Suitable emulsions will typically contain up to 20% oil, for example, between 5 and 20%. The fat emulsion will preferably comprise fat droplets between 0.1 and 1.0 μ m, particularly 0.1 and 0.5 μ m, and have a pH in the range of 5.5 to 8.0.

Particularly preferred emulsion compositions are those prepared by mixing a compound of formula (I) with IntralipidTM or the components thereof (soybean oil, egg phospholipids, glycerol and water).

Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as set out above. Preferably the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably sterile pharmaceutically acceptable solvents may be nebulised by use of inert gases. Nebulised solutions may be breathed directly from the nebulising device or the nebulising device may be attached to a face mask, tent or intermittent positive pressure breathing machine. Solution, suspension or powder compositions may be administered, preferably orally or nasally, from devices which deliver the formulation in an appropriate manner.

For topical administration, for example as a cream, ointment or lotion, pharmaceutically acceptable carriers are, for example, water, mixtures of water and water-miscible solvents such as lower alkanols or arylalkanols, vegetable oils, polyalkylene glycols, petroleum based jelly, ethyl cellulose, ethyl oleate, carboxymethylcellulose, polyvinylpyrrolidone, isopropyl myristate and other conventionally-employed non-toxic, pharmaceutically acceptable organic and inorganic carriers. The pharmaceutical preparation may also contain non-toxic auxiliary substances such as emulsifying,

preserving, wetting agents, bodying agents and the like, as for example, polyethylene glycols 200, 300, 400 and 600, carbowaxes 1,000, 1,500, 4,000, 6,000 and 10,000, antibacterial components such as quaternary ammonium compounds, phenylmercuric salts known to have cold sterilizing properties and which are non-injurious in use, thimerosal, methyl and propyl paraben, benzyl alcohol, phenyl ethanol, buffering ingredients such as sodium chloride, sodium borate, sodium acetates, gluconate buffers, and other conventional ingredients such as sorbitan monolaurate, triethanolamine, oleate, polyoxyethylene sorbitan monopalmitate, dioctyl sodium sulfosuccinate, monothioglycerol, thiosorbitol, ethylenediamine tetraacetic acid, and the like.

The compounds of formula (I) are of value in the treatment of a wide variety of clinical conditions which are characterised by the presence of an excess of tachykinin, in particular substance P, activity. These may include disorders of the central nervous system such as anxiety, depression, psychosis and schizophrenia; epilepsy; neurodegenerative disorders such as dementia, including senile dementia of the Alzheimer type, Alzheimer's disease and Down's syndrome; demyelinating diseases such as MS and ALS and other neuropathological disorders such as peripheral neuropathy, for example diabetic and chemotherapy-induced neuropathy, and postherpetic and other neuralgias; small cell carcinomas such as small cell lung cancer; respiratory diseases, particularly those associated with excess mucus secretion such as chronic obstructive airways disease, bronchopneumonia, chronic bronchitis, cystic fibrosis and asthma, and bronchospasm; inflammatory diseases such as inflammatory bowel disease, psoriasis, fibrositis, osteoarthritis, rheumatoid arthritis, pruritis and sunburn; allergies such as eczema and rhinitis; hypersensitivity disorders such as poison ivy; ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, and the like; ophthalmic conditions associated with cell proliferation such as proliferative

vitreoretinopathy; cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis; addiction disorders such as alcoholism; stress related somatic disorders; reflex sympathetic dystrophy such as shoulder/hand syndrome; dysthymic disorders; adverse immunological reactions such as rejection of transplanted tissues and disorders related to immune enhancement or suppression such as systemic lupus erythematosus; gastrointestinal (GI) disorders and diseases of the GI tract such as disorders associated with the neuronal control of viscera, ulcerative colitis, Crohn's disease, irritable bowel syndrome and emesis, including acute, delayed or anticipatory emesis such as emesis induced by chemotherapy, radiation, toxins, viral or bacterial infections, pregnancy, vestibular disorders, motion, surgery, migraine, and variations in intracranial pressure, in particular, for example, drug or radiation induced emesis or post-operative nausea and vomiting; disorders of bladder function such as cystitis, bladder detrusor hyper-reflexia and incontinence; fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis; disorders of blood flow caused by vasodilation and vasospastic diseases such as angina, migraine and Reynaud's disease; and pain or nociception, for example, that attributable to or associated with any of the foregoing conditions, especially the transmission of pain in migraine.

The compounds of formula (I) are also of value in the treatment of a combination of the above conditions, in particular in the treatment of combined post-operative pain and post-operative nausea and vomiting.

The compounds of formula (I) are particularly useful in the treatment of emesis, including acute, delayed or anticipatory emesis, such as emesis induced by chemotherapy, radiation, toxins, pregnancy, vestibular disorders, motion, surgery, migraine, and variations in intracranial pressure. Most especially, the compounds of formula (I) are of use in the treatment of emesis

induced by antineoplastic (cytotoxic) agents including those routinely used in cancer chemotherapy.

Examples of such chemotherapeutic agents include alkylating agents, for example, nitrogen mustards, ethyleneimine compounds, alkyl sulphonates and other compounds with an alkylating action such as nitrosoureas, cisplatin and dacarbazine; antimetabolites, for example, folic acid, purine or pyrimidine antagonists; mitotic inhibitors, for example, vinca alkaloids and derivatives of podophyllotoxin; and cytotoxic antibiotics.

Particular examples of chemotherapeutic agents are described, for instance, by D. J. Stewart in *Nausea and Vomiting: Recent Research and Clinical Advances*, Eds. J. Kucharczyk et al, CRC Press Inc., Boca Raton, Florida, USA (1991) pages 177-203, especially page 188. Commonly used chemotherapeutic agents include cisplatin, dacarbazine (DTIC), dactinomycin, mechlorethamine (nitrogen mustard), streptozocin, cyclophosphamide, carmustine (BCNU), lomustine (CCNU), doxorubicin (adriamycin), daunorubicin, procarbazine, mitomycin, cytarabine, etoposide, methotrexate, 5-fluorouracil, vinblastine, vincristine, bleomycin and chlorambucil [R. J. Gralla et al in *Cancer Treatment Reports* (1984) 68(1), 163-172].

The compounds of formula (I) are also of use in the treatment of emesis induced by radiation including radiation therapy such as in the treatment of cancer, or radiation sickness; and in the treatment of post-operative nausea and vomiting.

It will be appreciated that the compounds of formula (I) may be presented together with another therapeutic agent as a combined preparation for simultaneous, separate or sequential use for the relief of emesis. Such combined preparations may be, for example, in the form of a twin pack.

A further aspect of the present invention comprises the compounds of formula (I) in combination with a 5-HT₃ antagonist, such as ondansetron,

granisetron or tropisetron, or other anti-emetic medicaments, for example, a dopamine antagonist such as metoclopramide. Additionally, a compound of formula (I) may be administered in combination with an anti-inflammatory corticosteroid, such as dexamethasone. Furthermore, a compound of formula (I) may be administered in combination with a chemotherapeutic agent such as an alkylating agent, antimetabolite, mitotic inhibitor or cytotoxic antibiotic, as described above. In general, the currently available dosage forms of the known therapeutic agents for use in such combinations will be suitable.

When tested in the ferret model of cisplatin-induced emesis described by F. D. Tattersall *et al*, in *Eur. J. Pharmacol.*, (1993) 250, R5-R6, the compounds of the present invention were found to attenuate the retching and vomiting induced by cisplatin.

The compounds of formula (I) are also particularly useful in the treatment of pain or nociception and/or inflammation and disorders associated therewith such as, for example, neuropathy, such as diabetic and chemotherapy-induced neuropathy, postherpetic and other neuralgias, asthma, osteoarthritis, rheumatoid arthritis and especially migraine.

The present invention further provides a compound of formula (I) for use in therapy.

According to a further or alternative aspect, the present invention provides a compound of formula (I) for use in the manufacture of a medicament for the treatment of physiological disorders associated with an excess of tachykinins, especially substance P.

The present invention also provides a method for the the treatment or prevention of physiological disorders associated with an excess of tachykinins, especially substance P, which method comprises administration to a patient in need thereof of a tachykinin reducing amount of a compound of formula (I) or a composition comprising a compound of formula (I).

For the treatment of certain conditions it may be desirable to employ a compound according to the present invention in conjunction with another pharmacologically active agent. For example, for the treatment of respiratory diseases such as asthma, a compound of formula (I) may be used in conjunction with a bronchodilator, such as a β_2 -adrenergic receptor antagonist or tachykinin antagonist which acts at NK-2 receptors. The compound of formula (I) and the bronchodilator may be administered to a patient simultaneously, sequentially or in combination.

The present invention accordingly provides a method for the treatment of a respiratory disease, such as asthma, which method comprises administration to a patient in need thereof of an effective amount of a compound of formula (I) and an effective amount of a bronchodilator.

The present invention also provides a composition comprising a compound of formula (I), a bronchodilator, and a pharmaceutically acceptable carrier.

The excellent pharmacological profile of the compounds of the present invention offers the opportunity for their use in therapy at low doses thereby minimising the risk of unwanted side effects.


In the treatment of the conditions associated with an excess of tachykinins, a suitable dosage level is about 0.001 to 50 mg/kg per day, in particular about 0.01 to about 25 mg/kg, such as from about 0.05 to about 10 mg/kg per day.

For example, in the treatment of conditions involving the neurotransmission of pain sensations, a suitable dosage level is about 0.001 to 25 mg/kg per day, preferably about 0.005 to 10 mg/kg per day, and especially about 0.005 to 5 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.

In the treatment of emesis using an injectable formulation, a suitable dosage level is about 0.001 to 10 mg/kg per day, preferably about 0.005 to 5 mg/kg per day, and especially 0.01 to 2 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.

It will be appreciated that the amount of a compound of formula (I) required for use in any treatment will vary not only with the particular compounds or composition selected but also with the route of administration, the nature of the condition being treated, and the age and condition of the patient, and will ultimately be at the discretion of the attendant physician.

The compounds of the formula (I) may be prepared by a process which comprises reacting a compound of the formula (II) with a compound of the formula (III)



15

wherein A¹, A², R¹, R², R³, R⁴, R⁵, R⁶, R⁷, m and n are as defined for formula (I), R³ is as defined for formula (I) except that any reactive moiety R³ or R⁴ is protected; and one of R³⁰ and R³¹ represents a leaving group and the other represents a OH or NR¹⁹ group where R¹⁹ is as defined for formula (I); in the presence of base followed by deprotection if required.

Suitably R³⁰ represents XH and R³¹ represents a leaving group.


Suitable leaving groups include halo, e.g. chloro, bromo or iodo, or sulphonate derivatives such as tosylate or mesylate.

The reaction is conveniently carried out in a suitable organic solvent, such as an ether, e.g. 1,2-dimethoxyethane, at a temperature in the region of 5 0°C. Favoured bases of use in the reaction include alkali metal amides and hydrides, such as potassium bis(trimethylsilyl)amide or potassium hydride. Suitable, sodium hydride is used.

Compounds of formula (I) may also be prepared from different compounds of formula (I) by interconversion processes. In particular, 10 interconversion processes may be used to vary the group R³. For example, compounds of formula (I) wherein R³ is other than H may be prepared from the corresponding compounds of formula (I) wherein R³ is H by conventional methods, such as reaction with a compound R³-Hal, where Hal represents halo, in the presence of a base. Suitable reagents and conditions will be 15 readily apparent to those skilled in the art and are illustrated by the accompanying Examples. Suitable bases include organic bases, such as tertiary amines, e.g. triethylamine, and inorganic bases, such as alkali metal carbonates, e.g. sodium carbonate. Compounds of formula (I) wherein R³ is COR⁹ may also be prepared from compounds of formula (I) wherein R³ is H 20 by, for example, reaction with an appropriate acid anhydride. Compounds of formula (I) wherein R³ is C₁₋₆alkyl may be prepared from corresponding compounds of formula (I) wherein R³ is COR⁹ by reduction using, for example, borane or a borohydride such as sodium cyanoborohydride. Suitable procedures will be readily apparent to those skilled in the art. 25 Compounds of formula (I) wherein R³ is C₁₋₆alkyl substituted by CONR¹⁰R¹¹ may be prepared from corresponding compounds of formula (I) wherein R³ is C₁₋₆alkyl substituted by CO₂R¹⁰ by treatment with ammonia or an amine of formula NR¹⁰R¹¹.

The intermediates of formula (II) above wherein R³⁰ is NR¹⁶ may be prepared from the corresponding intermediates of formula (II) wherein R³⁰ represents OH.

Intermediates of formula (II) above wherein R³⁰ is OH and R⁶ and R⁷ both represent H may be prepared from corresponding compounds of formula (IV):



wherein A¹, A², R², R³, m and n are as defined for formula (II) above and R⁴⁰ represents hydroxy or alkoxy by reduction. Suitable reducing agents will be readily apparent to one skilled in the art and include, for example, metallic hydrides, such as lithium aluminium hydride.

Intermediates of formula (II) wherein R³⁰ is OH and one of R⁶ and R⁷ is C₁₋₆alkyl and the other of R⁶ and R⁷ is H may be prepared from compounds of formula (IV) wherein R⁴⁰ is H, by reaction with a Grignard reagent of formula MgHalR⁶ or MgHalR⁷, wherein R⁶ and R⁷ are as previously defined and Hal is halo such as chloro, bromo or iodo.

Intermediates of formula (II) wherein R³⁰ is OH and both of R⁶ and R⁷ represent C₁₋₆alkyl may be prepared from compounds of formula (IV) wherein R⁴⁰ is alkoxy by reaction with Grignard reagents of formulae MgHalR⁶ and MgHalR⁷, as above defined. Suitable reaction conditions will be readily apparent to those skilled in the art.

Compounds of formula (IV) wherein R⁴⁰ is H may be prepared from compounds of formula (IV) wherein R⁴⁰ is alkoxy by reduction. Suitable reducing agents will be readily apparent to those skilled in the art and include, for example, where R⁴⁰ is alkoxy, diisobutylaluminium hydride.


Intermediates of formula (II) wherein R³⁰ is a leaving group may be prepared from compounds of formula (II) wherein R³⁰ is OH, for example, by reaction with a thionyl halide, a mesyl halide or a tosyl halide.

Where they are not commercially available, the intermediates of formula (III) above may be prepared by the procedures described in the accompanying Examples or by alternative procedures which will be readily apparent to one skilled in the art.

Compounds of formula (IV) are commercially available, or may be prepared by known procedures.

For example, suitable methods for the preparation of compounds of formula (IV) are described in European Patent Application no. 0 337 167, *J. Am. Chem. Soc.*, 81, 1201 (1959), *J. Med. Chem.*, 17, 453 (1974) and *J. Med. Chem.*, 24, 218 (1981).

In general, compounds of formula (IV) wherein R³ is H, R⁴⁰ is alkoxy and n is 1 or 2 may be prepared by cyclisation of an intermediate of formula (V)




wherein R², R⁴⁰, n and m are as previously defined, and Hal represents halo, for example, chloro or bromo, in the presence of a reducing agent such

as hydrogen in the presence of a catalyst such as platinum oxide or palladium on charcoal.

The reaction is conveniently effected in a suitable organic solvent, such as an ether, for example, tetrahydrofuran.

5 Analogous methods may be used to produce compounds of the formula (IV) substituted by A¹ and A² wherein A¹ and A² are as defined in relation to formula (II).

10 Intermediates of formula (V) may be prepared by reaction of compounds of formula (VI) with compounds of formula (VII)




15 wherein R², R⁴⁰, n, m and Hal are as previously defined, in the presence of a base. Analogues of the compounds of formula (V) containing groups A¹ and A² as previously defined may be prepared in analogous manner.


20 Suitable bases of use in the reaction include alkali metal hydrides, such as, for example, sodium hydride. The reaction is conveniently effected in a suitable organic solvent, such as an ether, for example, tetrahydrofuran, suitably at elevated temperature, such as the reflux temperature of the chosen solvent.

Compounds of formulae (VI) and (VII) are commercially available, or may be prepared from commercially available starting materials using conventional procedures well known to those skilled in the art.

25 Compounds of formula (IV) wherein R⁴⁰ is alkoxy and n is other than zero may in general be prepared from the corresponding compounds of formula (VIII)




5 wherein A¹, A², R³, R⁴⁰ and m are as previously defined and n is 1 or 2 by treatment with a base and reaction of the resulting nucleophile with a reagent suitable to introduce the group R², such as an activated aryl moiety, for example:



10

wherein R^X is H or halo, such as chloro; an aryl iodide in the presence of nickel bromide (*J. Am. Chem. Soc.*, 99, 4833 (1977)); or a hypervalent aryl iodide (*Synthesis*, 709 (1984)).

15 Compounds of formula (VIII) may be prepared from the corresponding intermediates of formula (IX)




wherein A¹, A², R³, m and n are as defined for formula (VIII) by conventional methods, for example, by sequential reaction with lithio-2-trimethylsilyl-1,3-dithiane and an alcohol of formula R⁴⁰H, where R⁴⁰ is alkoxy, in the presence of an acid, such as a mineral acid, for example, hydrochloric acid.

Still further procedures suitable for the preparation of compounds of formula (IV) will be readily apparent to those skilled in the art.

Compounds of the formula (I) wherein R³ and R⁵ are hydrogen may also be prepared from a corresponding compound of the formula (X):

10



wherein A¹, A², R¹, R², R⁶, R⁷, X, m and n are as defined in relation to formula (I), and R³¹ is a protecting group and any reactive group is protected, by conventional processes followed by deprotection if required.

15

Most aptly the compound of the formula (X) is one in which R³¹ represents a protecting group such as t-butoxycarbonyl.


Similarly, for compounds of the formula (X) in which X is not oxygen, X preferably represents a protected amino group, such as a t-butoxycarbonyl protected amino group.

20

Thus for example for compounds wherein R⁴ is CH₂OH, the compound of the formula (X) may be treated with a borane such as BH₃, in a suitable solvent such as tetrahydrofuran, followed by treatment with a peroxide, for example hydrogen peroxide, in the presence of a base, such as sodium hydroxide.

Compounds wherein R^4 is CH_2OH may be converted into compounds wherein R^4 is $(CH_2)_pOR^{16}$ where p is 1 and R^{16} is as defined in relation to formula (I) by reaction with a halide of the formula $R^{16}Hal$, where Hal is as previously defined, in the presence of a suitable base such as sodium 5 hydride.

A group of particularly suitable intermediates may be represented by formula (XI):





10

wherein R^1 , R^2 , R^6 , R^7 , X , n and m are as defined in relation to formula (I) and PG represents a protecting group and in particular t-butoxycarbonyl.

The CH_2BH_2 moiety may be converted into R^4 groups by known methods.


15

Compounds of the formula (I) wherein R^3 and R^5 are hydrogen, X is O or S and R^4 is a CO_2R^{16} group can be prepared by reaction of a compound of the formula (XII) with one of formula (XIII):



wherein A¹, A², R¹, R², R⁶, R⁷, m and n are as defined in relation to formula (I), X is O or S, R³¹ is a protecting group and R⁴⁰ is a C₁₋₆alkyl group or a readily removable group. The reaction is effected in the presence of a catalyst such as rhodium(II)acetate in a suitable solvent, for example, a hydrocarbon such as toluene at elevated temperature, conveniently at reflux. Thereafter, R³¹ may be replaced by H and, if desired, the readily removable ester may be replaced by H or a salting ion in conventional manner. The CO₂R⁴⁰ group may also be converted to other R⁴ groups by known methods.

Another group of particularly useful intermediates may be represented by formula (XIV):



wherein R¹, R², R⁶, R⁷, X, n and m are as defined in relation to formula (I) and PG represents a protecting group and in particular t-butoxycarbonyl.

The CO₂CH₃ moiety may be converted into other R⁴ groups by known methods. Thus, for example, reaction with a Grignard reagent of formula R^cMgHal where R^c is an alkyl group and Hal is as previously defined will give compounds where R⁴ is a tertiary alcohol. Secondary alcohols may be prepared firstly by reduction of the ester moiety to an aldehyde using, for example, diisobutylaluminium hydride, followed by reaction with either R^cLi or R^cMgHal.


The aldehyde may also be used as a precursor for alkenyl intermediates where the group at position R⁴ has the formula -CH=CHR^d, where R^d is (CH₂)_sNR¹⁰R¹¹, (CH₂)_sCO₂R¹⁶, (CH₂)_sCONR¹⁰R¹¹ or (CH₂)_sNR¹⁰COR¹⁸ (where s is 0, 1 or 2 and R¹⁰, R¹¹ and R¹⁸ are as previously defined). These compounds may be prepared by a Wittig reaction using, for example, Ph₃P=CHR^d or (EtO)₃P(O)=CHR^d. These alkenyl intermediates may be reduced using, for example, catalytic hydrogenation to give compounds wherein R⁴ is (CH₂)_pNR¹⁰R¹¹, (CH₂)_pCO₂R¹⁶, (CH₂)_pCONR¹⁰R¹¹ or (CH₂)_pNR¹⁰COR¹⁸ and p is 2 to 4.

Compounds wherein R⁴ is CONR¹⁰R¹¹ may be prepared by the reaction of a compound of formula (XIV) with an amine of the formula HNR¹⁰R¹¹ by known methods. Subsequent reduction using, for example, borane in tetrahydrofuran may be used to give a compound wherein R⁴ is (CH₂)_pNR¹⁰R¹¹ in which p is 1. Where one or both of R¹⁰ and R¹¹ in the resultant amine is a hydrogen atom, the amine may be further converted into a compound wherein R⁴ is (CH₂)_pNR¹⁰COR¹⁸ by reaction with, for example, an acyl chloride of the formula R¹⁶COCl by known methods.

If a compound of the formula (I) is required in which R⁵ is an alkyl group it may be prepared via a corresponding compound of the formula (I) in which R⁴ is CO₂R⁴⁰ group by reaction with KHMDS and an alkyl iodide,

followed if desired by replacement of a readily removable group R^{40} by H or a salting ion. The CO_2R^{40} may also be converted to other R^4 groups by known methods:

Intermediates of formula (II) wherein R^{30} is NR^{19} and R^6 and R^7 are hydrogen may be prepared by reduction of a corresponding compound of the formula (XV):




10 wherein R^2 , R^3 , A^1 , A^2 , n and m are as defined in relation to formula (II).


The reduction may be effected using a reducing agent such as lithium aluminium hydride in order to produce a compound in which R^{19} is hydrogen (which in general is preferred). This may be followed by reductive amination to produce a compound in which R^{19} is a C_{1-4} alkyl group in conventional manner.

Compounds of the formula (XV) can be prepared from the corresponding halo compound by reaction with, for example, KCN using known methods. Such halo compounds are either commercially available or may be prepared in an analogous manner to commercial compounds.

20 Intermediates of formula (II) wherein R^{30} is OH and R^6 and R^7 are hydrogen have the general formula (XVI):



wherein A^1 , A^2 , R^2 , R^3 , n and m are as defined in relation to formula (I).
 These compounds may be prepared by reduction of a corresponding
 5 compound of the formula (XVII):



10 using lithium aluminium hydride in conventional manner. Most aptly the reduction is performed on a compound of the formula (XVI) in which R^3 is hydrogen. After reduction R^3 is aptly replaced by a t-butoxycarbonyl group which acts as a favoured protecting group.

15 Compounds of the formula (XVII) wherein R^3 is hydrogen may be obtained commercially or prepared in an analogous manner to commercial compounds.

Compounds of formula (X) may be prepared from a corresponding compound in which the $=\text{CH}_2$ moiety is an $=\text{O}$ group, by reaction with dimethyltitanocene in toluene according to the method of N. A. Petasis *et al*, *J. Am. Chem. Soc.*, (1990) 112(17), 6392. Alternatively, titanium tetrachloride/zinc dust/tetrahydrofuran/dichloromethane may be used according to the method of P. Kocienski and M. Mortimore, *Tet. Lett.*, (1988)

29(27), 3375. When X is an oxygen atom, this ester precursor may be prepared by conventional methodology from an alcohol of formula (XVI) and an appropriate benzoic acid derivative in the presence of a suitable coupling agent such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and a base such as 4-dimethylaminopyridine. The reaction is conveniently effected in a solvent such as dimethylformamide.

5 It will be appreciated that a mixture of diastereomers may be resolved by methods known in the art. Thus, for example, an intermediate of formula (XIV) may be resolved by the preparation of a chiral auxiliary using, for instance, (R)-4-benzyl-2-oxazolidone. Following resolution by, for example, chromatography, the oxazolidone moiety may be removed using a reducing agent such as lithium borohydride to yield compounds wherein R⁴ is CH₂OH and R⁵ is H. The less favoured diastereomer may be isomerised to give a further mixture of diastereomers and the resolution procedure repeated.

10 During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in *Protective Groups in Organic Chemistry*, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene and P.G.M. Wuts, *Protective Groups in Organic Synthesis*, John Wiley & Sons, 15 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

20 The exemplified compounds of this invention were tested by the methods set out at pages 36 to 39 of International Patent Specification No. WO 93/01165. The compounds were found to be active with IC₅₀ at the NK1 receptor of less than 150nM.

25 The compounds of this invention may be formulated as specifically illustrated at pages 35 to 36 of International Patent Specification No. WO 93/01165.

The following non-limiting examples serve to illustrate the present invention:

EXAMPLE 1

5 4-Phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)methyl)piperidine Hydrochloride

a) 1-tert-Butoxycarbonyl-4-phenyl-4-hydroxymethylpiperidine
4-Phenyl-4-carboxy piperidine tosylate (10g) was added portionwise to a
10 solution of lithium aluminium hydride (1.52g) in dry tetrahydrofuran (100ml) at
0°C. After addition was complete the reaction mixture was warmed to reflux
for 30 minutes and then allowed to cool to room temperature. The reaction
was then quenched by addition of 2N sodium hydroxide solution until a white
granular precipitate formed. The mixture was filtered and the filtrate
15 extracted with ethyl acetate (200ml), dried (MgSO_4), filtered and solvent
removed to afford a clear oil. The residual oil was taken up in
dichloromethane (50ml) and di-*tert*-butyl-dicarbonate (1.9g) added. The
resulting mixture was stirred at room temperature for 18 hours. The solvent
was removed and the residual oil subjected to chromatography on silica gel
20 to afford the title compound as a colourless oil. ^1H NMR (360MHz, CDCl_3) δ
1.43 (9H, s), 1.75 (2H, td, $J=11.0, 10\text{Hz}$), 2.17 (2H, m), 3.05 (2H, td, $J=11.0,$
1.0Hz), 3.55 (2H, s), 3.73 (2H, m), 7.24-7.41 (5H, m); MS (Cl^+) 292 ($\text{M}+\text{H}$)⁺.

b) 1-tert-Butoxycarbonyl-4-phenyl-4-[3,5-bis(trifluoromethyl)benzoyloxymethyl]piperidine
25 1-(3-Dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride (897mg) was
added to a stirred solution of 3,5-bis(trifluoromethyl) benzoic acid (292mg)
and 4-dimethylaminopyridine (483mg) in dry dimethylformamide (20ml). The
resulting solution was stirred for 30 minutes then the compound of step (a)

above (1.0g) was added. The resulting solution was stirred at room temperature for 19 hours. At this time the reaction was diluted with water (200ml) and extracted into ethyl acetate. The organic layers were separated, washed with water, brine, and dried over $MgSO_4$. Filtration and removal of solvent under reduced pressure afforded a yellow oil. Purification by chromatography on silica gel (20% ethyl acetate/n-hexane) afforded the product as a clear oil. 1H NMR (360MHz, $CDCl_3$) δ 1.4 (9H, s), 1.95 (2H, m), 2.3 (2H, m), 3.03 (2H, m), 3.8 (2H, m), 4.35 (2H, s), 7.0-7.2 (5H, m), 8.01 (1H, s), 8.25 (2H, s).

10

c) 1-tert-Butoxycarbonyl-4-phenyl-4-[1-(3,5-bis(trifluoromethyl)phenyl)vinyloxymethyl]piperidine

15

Titanium tetrachloride (1.06g) was added to cooled (0°C) stirred tetrahydrofuran under a dry nitrogen atmosphere. After the exotherm had subsided the solution was allowed to warm to room temperature and tetramethylethylene diamine (1.69g) added followed 15 minutes later by freshly activated zinc dust (819mg). The resulting mixture was stirred for 30 minutes at room temperature at which point dibromomethane (0.21ml) and the compound of step (b) above (716mg) were added. The reaction was allowed to proceed for 18 hours at room temperature. After this time the reaction was quenched with saturated K_2CO_3 (7ml) and diluted with diethyl ether. The resulting black suspension was filtered through a plug of grade III neutral alumina, eluting with 1% triethylamine/diethyl ether. The filtrate was dried over $MgSO_4$, filtered and the solvent removed under reduced pressure. The residual oil was purified by chromatography on silica gel (10% ethyl acetate/ n-hexane) to afford the title compound. 1H NMR (360MHz, $CDCl_3$) δ 1.2 (9H, s), 1.95 (2H, m), 2.38 (2H, m), 3.05 (2H, m), 3.8 (2H, s), 3.95 (2H, m), 4.21 (1H, d, $J=1.0Hz$), 4.63 (1H, d, $J=1.0Hz$), 7.1-7.3 (5H, m), 7.7 (1H, s), 7.76 (2H, s).

d) 1-tert-Butoxycarbonyl-4-phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)methyl)piperidine

The compound of step (c) above was treated with BH₃.tetrahydrofuran (5ml of a 1M solution in tetrahydrofuran) under an atmosphere of nitrogen for 2 hours. A mixture of 4N NaOH (10ml) and H₂O₂ (5ml of a 29% solution in water) was added and the reaction stirred for 3 hours, then extracted with diethyl ether. The ethereal extracts were washed with sodium bisulphite solution then dried (Na₂SO₄) and concentrated. The residue was purified by chromatography on silica gel eluting with ethyl acetate-petroleum ether (3:7) to give the title compound as a colourless oil.

e) 4-Phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)methyl)piperidine Hydrochloride

The compound of step (d) above was dissolved in methanolic hydrogen chloride for 2 hours then concentrated and triturated with diethyl ether and filtered to give the title compound as a white solid, m.p. 198-202°C. Analysis Calcd. for C₂₂H₂₃F₆NO₂.HCl.0.5H₂O: C, 53.61; H, 5.11; N, 7.84; Found: C, 53.92; H, 4.84; N, 7.85.

20

EXAMPLE 2

4-Phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-2-methoxyethoxy)methyl)piperidine Hydrochloride

The compound of Example 1(d) above (200mg) in dimethoxyethane (1ml) was stirred with sodium hydride (60% in oil, 100mg) for one hour. Iodomethane (0.5ml) was added and the reaction was stirred for 16 hours and then poured into water, extracted with ethyl acetate, and washed with aqueous sodium chloride. The organic layer was dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography on silica using

ethyl acetate/petroleum ether (1:4) to yield an oil which was dissolved in ethereal hydrogen chloride and stirred for 16 hours. The solvent was removed to yield the title compound. ^1H NMR (360MHz, d_6 -DMSO) δ 7.98 (1H, s), 7.72 (2H, s), 7.41-7.26 (5H, m), 4.65 (1H, t, $J=4.7\text{Hz}$), 3.53-3.16 (6H, m), 3.20 (3H, s), 2.81-2.69 (2H, m), 2.47-2.33 (2H, m), 2.23-2.02 (2H, m). MS (Cl $^+$) 462 (M+H) $^+$.

EXAMPLE 3

10 4-Phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-2-ethoxyethoxy)methyl)piperidine Hydrochloride

This was prepared in a similar manner to Example 2 using the compound of Example 1(d) and iodoethane. ^1H NMR (360MHz, d_6 -DMSO) δ 7.97 (1H, s), 7.72 (2H, s), 7.41-7.10 (5H, m), 4.63 (1H, t, $J=4.7\text{Hz}$), 3.55-3.29 (6H, m), 3.28-3.10 (2H, m), 2.75-2.65 (2H, m), 2.38-2.24 (2H, m), 2.14-2.00 (2H, m), 1.00 (3H, t, $J=7.2\text{Hz}$). MS (Cl $^+$) 476 (M+H) $^+$.

EXAMPLE 4

20 4-Phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-2-cyclopropylmethoxyethoxy)methyl)piperidine Hydrochloride

This was prepared in a similar manner to Example 2 using the compound of Example 1(d) and cyclopropyl methyl bromide. ^1H NMR (360MHz, d_6 -DMSO) δ 7.91 (1H, s), 7.66 (2H, s), 7.35-7.19 (5H, m), 4.58 (1H, t, $J=4.7\text{Hz}$), 3.50-3.06 (6H, m), 2.76-2.61 (2H, m), 2.33-2.17 (2H, m), 2.08-1.94 (2H, m), 0.84-0.77 (1H, m), 0.36-0.30 (2H, m), 0.01-0.06 (2H, m). MS (Cl $^+$) 502 (M+H) $^+$.

25

EXAMPLE 5

4-Phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-2-methoxycarbonylmethoxyethoxy)methyl)piperidine Hydrochloride

This was prepared in a similar manner as Example 2 using the compound of Example 1(d) and methyl bromoacetate. ^1H NMR (360MHz, d_6 -DMSO) δ 7.98 (1H, s), 7.75 (2H, s), 7.41-7.24 (5H, m), 4.68 (1H, t, $J=5\text{Hz}$), 4.11 (2H, s), 3.62 (3H, s), 3.69-3.30 (4H, m), 3.29-3.10 (2H, m), 2.78-2.60 (2H, m), 2.39-2.00 (4H, m). MS (Cl $^+$) 520 (M+H) $^+$.

EXAMPLE 6

4-Phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-2-acetoxyethoxy)methyl)piperidine Hydrochloride

The compound of Example 1(d) (1.2g) was dissolved in dichloromethane (50ml) and treated with triethylamine (0.5ml) and acetylchloride (0.5ml). The reaction was stirred for 16 hours, poured into citric acid and washed with brine, saturated sodium bicarbonate solution, dried (MgSO_4) filtered and evaporated to yield an oil which was purified by chromatography on silica gel using ethyl acetate/petroleum ether (1:4) to yield an oil. This was dissolved in dry ethereal hydrogen chloride and stirred for 2 hours. The solvent was removed to yield the title compound. ^1H NMR (360MHz, d_6 -DMSO) δ 8.01 (1H, s), 7.74 (2H, s), 7.40-7.27 (5H, m), 4.74 (1H, t, $J=3.6\text{Hz}$), 4.16 (2H, d, $J=3.6\text{Hz}$), 3.53-3.31 (1H, m), 3.30-3.14 (2H, m), 2.80-2.70 (2H, m), 2.5 (3H, s), 2.35-2.20 (2H, m), 2.19-1.92 (2H, m). MS (Cl $^+$) 490 (M+H) $^+$
Analysis Calcd. for $\text{C}_{24}\text{H}_{25}\text{F}_6\text{NO}_3\text{HCl.H}_2\text{O}$: C, 53.00; H, 5.19; N, 2.58;
Found C, 53.17; H, 4.97; N, 2.61%.

EXAMPLE 7

5-[(4-Phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)methyl)piperidin-1-ylmethyl]-2,4-dihydro-[1,2,4]triazol-3-one

The compound of Example 1 (3.2g) in dry dimethylformamide (50ml) was stirred for 2 hours with methoxycarbonyl chloromethyl imidrazone (1.15g) and potassium carbonate (3.5g). The mixture was heated to reflux for 2 hours

then cooled, diluted with water and extracted with diethyl ether 3 times. The combined extracts were washed with water, dried (Na_2SO_4) and concentrated to give a residue which was purified by chromatography on silica gel eluting with 10% methanol/dichloromethane to give the title compound as a white solid, mp 105-106°C; MS (Cl^+) 545 ($\text{M}+\text{H}^+$); ^1H NMR (360MHz, d_6 -DMSO) δ 1.84-2.22 (6H, m), 2.42-2.56 (2H, m), 3.23 (1H, d, $J=9\text{Hz}$), 3.31 (2H, s), 3.38-3.56 (3H, m), 4.39 (1H, t, $J=5.4\text{Hz}$), 4.75 (1H, t, $J=5.8\text{Hz}$), 7.18 (1H, t, $J=7\text{Hz}$), 7.26-7.37 (4H, m), 7.68 (2H, s) and 7.94 (1H, s).

10.

EXAMPLE 8

4-Phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)methyl)-1-(2-(1-pyrrolidinyl)acetamido)piperidine Hydrochloride

15

(1-Pyrrolidinyl)acetic acid (0.68g) in dry dimethyl formamide (20ml) was treated with triethylamine (1.38ml) and cooled to -30°C. iButyl chloroformate (0.55ml) was added and the reaction stirred for 10 minutes before adding the compound of Example 1 (1.0g). The solution was allowed to warm slowly to room temperature then stirred for 16 hours. The solution was concentrated under reduced pressure then ethyl acetate was added and washed with aqueous sodium chloride, then dried and concentrated to give an oil which was dissolved in methanol and stirred with potassium carbonate for 1 hour. The solvent was evaporated and the residue partitioned between ethyl acetate and aqueous sodium chloride. The organic solution was dried (Na_2SO_4) and concentrated to give a residue which was purified by chromatography on neutral alumina eluting with 1%

20

methanol/dichloromethane. The resulting product was treated with ethereal hydrogen chloride to give a white solid which was recrystallised from ethyl acetate to give the title compound; mp 110-112°C; MS (Cl^+) 559 ($\text{M}+\text{H}^+$); ^1H NMR (360MHz, d_6 -DMSO) δ 1.78-2.32 (8H, m), 2.96-3.18 (4H, m), 3.29 (1H, d, $J=9.1\text{Hz}$), 3.38-3.60 (6H, m), 3.80-3.95 (1H, m), 4.24-4.33 (1H, m), 4.38-

4.47 (2H, m), 7.23 (1H, t, $J=7.5\text{Hz}$), 7.34 (2H, t, $J=7.5\text{Hz}$), 7.41 (2H, t, $J=7.5\text{Hz}$), 7.68 (1H, s), 7.70 (1H, s) and 7.96 (1H, s).

EXAMPLE 9

5 Methyl 2-(4-phenylpiperidin-4-yl)methoxy-2-(3,5-bis(trifluoromethyl)phenyl)acetate Hydrochloride

a) Methyl 3,5-bis(trifluoromethyl)phenylacetate

3,5-Bis(trifluoromethyl)phenylacetic acid (10.0 g, 36.7mmol), was dissolved in methanol (150ml). The solution was cooled to 4°C under an atmosphere of dry nitrogen, and thionyl chloride (10ml) was added dropwise with vigorous stirring over 30 minutes. The mixture was warmed to room temperature, and then stirred for 1 hour. The solvents were evaporated at reduced pressure, the residue dissolved in diethyl ether (150ml), washed with saturated aqueous NaHCO_3 , dried (Na_2SO_4), and evaporated to afford the title compound (10.5g, 100%), as a colourless oil which was used without further purification.

b) Methyl 2-diazo-2-(3,5-bis(trifluoromethyl)phenyl)acetate

20 To methyl 3,5-bis(trifluoromethyl)phenylacetate (43.5g, 160mmol), in dry acetonitrile (250ml), cooled to -5°C , was added 2,4,6-triisopropyl benzenesulfonyl azide (52.7g). To the resulting solution was added 1,8-diazabicyclo[5.4.0]undec-7-ene (25.5ml), and the mixture was stirred at -5°C for 1 hour. The mixture was warmed to room temperature, and then stirred for 0.5 hour. The solvents were evaporated at reduced pressure and the residue purified by chromatography on silica gel (eluant 5% diethyl ether/petroleum ether), to afford the title compound as yellow prisms. I.R (film, NaCl) 1740, 2140 cm^{-1} .

c) Methyl 2-(1-tert-butoxycarbonyl-4-phenylpiperidin-4-yl)methoxy-2-(3,5-bis(trifluoromethyl)phenyl)acetate

To a solution of the product of Example 1(a) (8.6g, 30.8mmol) and rhodium acetate (20mg) in dry benzene (20ml) heated at reflux under an atmosphere of dry argon, was added dropwise with stirring over 25 hours, a solution of methyl 2-diazo-2-(3,5-bis(trifluoromethyl)phenyl)acetate (6.13g, 19.6mmol) in dry benzene (6ml), via a syringe pump. The resulting solution was heated for a further 1 hour, cooled to room temperature, and the solvents evaporated at reduced pressure. The residue was purified by chromatography on silica gel (eluant 25% to 40% diethyl ether/ petroleum ether), to afford the title compound as a colourless oil. ^1H NMR (250MHz, CDCl_3) δ 7.79 (1H, s), 7.70 (2H, s), 7.40- 7.21 (5H, m), 4.67 (1H, s), 3.77 (2H, m), 3.69 (3H, s), 3.67 (1H, d, $J=9\text{Hz}$), 3.36 (1H, d, $J=9\text{ Hz}$), 3.04 (2H, m), 2.25 (2H, m), 1.91 (2H, m), 1.44 (9H, s).

d) Methyl 2-(4-phenylpiperidin-4-yl)methoxy-2-(3,5-bis(trifluoromethyl)phenyl)acetate Hydrochloride

The product of step (c) above was dissolved in saturated methanolic hydrogen chloride, and allowed to stand at room temperature for 24 hours.

The solvents were evaporated at reduced pressure then toluene was added to the residue and evaporated at reduced pressure to afford the title compound as a colourless foam. Analysis Calcd. for $\text{C}_{23}\text{H}_{23}\text{F}_6\text{NO}_3\text{HCl}$.
0.5(H_2O): C, 53.03; H, 4.84; N, 2.69; Found: C, 52.78; H, 4.75; N, 2.75%. MS (Cl^+) 476 ($\text{M}+\text{H}$)⁺.

EXAMPLE 10

iso-Propyl 2-(4-phenylpiperidin-4-yl)methoxy-2-(3,5-bis(trifluoromethyl)phenyl)acetate Hydrochloride

The product of Example 9 (0.070g), was dissolved in propan-2-ol saturated with hydrogen chloride, and allowed to stand at room temperature for 48hours. The solvents were evaporated at reduced pressure then toluene was added to the residue and evaporated at reduced pressure. The resulting 5 gum was dissolved in acetonitrile (1ml), water (2ml) was added, and the solution freeze dried to afford the title compound as a colourless foam. Analysis Calcd. for $C_{25}H_{27}F_6NO_3 \cdot HCl$. 1.5(H₂O): C, 52.96; H, 5.51; N, 2.4; Found: C, 53.09; H, 5.26; N, 2.41%. MS (Cl⁺) 504 (M+H)⁺.

10

EXAMPLE 11

4-Phenyl-4-[1-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxy-2-methyl-propyloxy)methyl]piperidine Hydrochloride.

15

To the product of Example 9(c) (0.522g, 0.9mmol) dissolved in dry tetrahydrofuran (1ml) at -78°C under argon was added a solution of methylmagnesium chloride (1.0ml of a 3.0M solution in tetrahydrofuran). The mixture was stirred for 2 hours at -78°C then quenched by addition of saturated aqueous NH₄Cl, and warmed to room temperature. The reaction was partitioned between ethyl acetate and water; the organic layer was separated, dried (Na₂SO₄), and evaporated at reduced pressure. The residue 20 was purified by chromatography on silica gel (eluant 25% to 40% diethyl ether/ petroleum ether), to afford a colourless foam (0.318g). This was dissolved in saturated methanolic hydrogen chloride, and allowed to stand at room temperature for 24 hours. The solvents were evaporated at reduced pressure, and the residue partitioned between saturated aqueous NaHCO₃ 25 and ethyl acetate. The organic extracts were dried (Na₂SO₄) and evaporated at reduced pressure. The residue was purified by chromatography on grade (III) alumina (eluant 2% to 10% methanol / dichloromethane), to afford the the title compound as a colourless oil. 2N Aqueous hydrochloric acid (2ml), was added followed by acetonitrile to give a homogeneous solution, which

was then freeze dried. The resulting gum was dissolved in hot diethyl ether (10ml), excess petroleum ether was added, and the solvents evaporated at reduced pressure to afford the title compound as a colourless solid.

Analysis Calcd. for $C_{24}H_{27}F_6NO_2 \cdot HCl \cdot 0.5(H_2O)$: C, 55.34; H, 5.61; N, 2.69;

5 Found: C, 55.43; H, 5.70; N, 2.69%. MS (Cl⁺) 476 (M+H)⁺.

EXAMPLE 12

2-(4-Phenylpiperidin-4-yl)methoxy-2-(3,5-bis(trifluoromethyl)phenyl)acetamide Hydrochloride

10 Ammonia gas was passed through a solution of the product of Example 9 (0.644g) in dry methanol (50ml) at -15°C until saturated. The reaction flask was sealed with a rubber septum and allowed to stand at room temperature for 48 hours, then solvents were evaporated at reduced pressure. The residue was dissolved in acetonitrile (1ml) and 2N aqueous hydrochloric acid (2ml), and the solution freeze dried. The residue was boiled with ethyl acetate, allowed to cool, and the title compound collected by filtration as a colourless solid, mp 146 - 148°C. Analysis Calcd. for $C_{22}H_{22}F_6N_2O_2 \cdot HCl \cdot H_2O$: C, 51.32; H, 4.89; N, 5.44; Found: C, 51.28; H, 4.73; N, 5.84%. MS (Cl⁺) 461 (M+H)⁺.

20

EXAMPLE 13

4-Phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-aminoethoxy)methyl]piperidine Hydrochloride.

25 Ammonia gas was passed through a solution of the product of Example 9(c) (1.0g), in dry methanol (50ml), cooled at -15°C, until saturated. The reaction flask was sealed with a rubber septum, and allowed to stand at room temperature for 48 hours then the solvents were evaporated at reduced pressure. The residue was treated with borane-tetrahydrofuran complex (20ml of a 1.0M solution in tetrahydrofuran), and heated at reflux for 24

hours. After cooling to room temperature, methanol was added dropwise with caution to destroy excess reagent. The solvents were evaporated at reduced pressure, the residue dissolved in methanol (20ml), and the solution allowed to stand at room temperature for 24 hours. The residue obtained by 5 evaporation of the methanol at reduced pressure, was purified by chromatography on silica gel (eluant 5% methanol/dichloromethane), to afford the tbutoxycarbonyl-protected piperidine (0.39g). This was dissolved in saturated ethereal hydrogen chloride (10ml) and methanol (1ml) then allowed to stand at room temperature for 48 hours. The title compound was 10 collected as a colourless solid by filtration. Analysis Calcd. for $C_{22}H_{24}F_6N_2O$. 2(HCl): C, 50.88; H, 5.05; N, 5.39; Found: C, 50.82; H, 4.98; N, 5.26%. MS (Cl⁺) 447 (M+H)⁺.

EXAMPLE 14

15 (+)-4-Phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)methyl]piperidine Hydrochloride

a) 2- (1-tert-Butoxycarbonyl-4-phenylpiperidine-4-yl)methoxy-2-(3,5-bis(trifluoromethyl)phenyl)acetic acid
20 To a solution of methyl 2-[(1-tert-butoxycarbonyl-4-phenylpiperidin-4-yl)methoxy]-2-(3,5-bis(trifluoromethyl)phenyl)acetate (11g, 0.019mol) in methanol (100ml) at 0°C was added potassium hydroxide (3.2g, 5.7mmol), followed by water (3ml). The homogeneous solution was stirred at 0°C for 1 hour. The methanol was removed in vacuo and pH4 buffer (100ml) added 25 to the residue. The product was extracted into diethyl ether (2 x 100ml), the combined ethereal solutions dried ($MgSO_4$), filtered and evaporated in vacuo. The resulting white foam was used without further purification.

b) (4R)-3-[2-(1-*tert*-Butoxycarbonyl-4-phenylpiperidine-4-yl)methoxy-2-(3,5-bis(trifluoromethyl)phenyl)acetyl]-4-benzyl-2-oxazolidinone

The compound of step (a) above (1.0g, 1.7mmol) was dissolved in anhydrous dichloromethane (50ml). Dimethylformamide (0.05ml) was added followed by 5 oxalyl chloride (0.2ml, 2.3mmol) dropwise. After stirring at 25°C for 0.5 hours the solvent was removed in vacuo. The resulting residue was azeotroped with toluene (2 x 50ml) then, as a solution in anhydrous toluene (5ml), added at -78°C to the lithium anion of (4R)-4-benzyl-2-oxazolidinone (generated by adding n-BuLi (1.1ml, 1.6M, 1.7mmol) to a solution of (4R)-(+)-4-benzyl-2-oxazolidinone (0.301g, 1.7mmol) in tetrahydrofuran (5ml) at -78°C). The 10 resulting colorless solution was stirred at -78°C for a further 0.75 hours and quenched by addition of saturated ammonium chloride solution (30ml). The product was extracted into ethyl acetate (2 x 30ml) then the organic layer was dried over MgSO₄ and filtered. The clear oil obtained after removal of solvent in vacuo was purified by chromatography on silica gel eluting first with 20% 15 ethyl acetate/ hexane to obtain the title compound, diastereomer A (0.350g), and then with 30% ethyl acetate/hexane to obtain the title compound, diastereomer B (0.380g).

Diastereomer A was converted to a mixture (1:2) of diastereomer A and 20 diastereomer B by treating a solution in dichloromethane with anhydrous triethylamine for 16 hours. The solvents were evaporated and the mixture separated by chromatography as described above to obtain diastereomer B:

¹H NMR (250MHz, CDCl₃) δ 7.78 (s, 1H), 7.70 (s, 2H), 7.10 -7.30 (m, 8H), 6.88 (m, 2H), 5.86 (s, 1H), 4.62 (m, 1H), 4.06-4.12 (m, 2H), 3.68 (m, 2H), 25 3.54 (d, J=7Hz, 1H), 3.22 (d, J=7Hz, 1H), 2.96 (m, 3H), 2.54 (dd, J= 7, 2 Hz, 1H), 2.1 (m, 2H), 1.8 (m, 2H), 1.34 (s, 9H).

c) (+)-1-*tert*-Butoxycarbonyl-4-phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)methyl]piperidine

The product of step (b), diastereomer B above (1.8g, 2.5mmol), was dissolved in diethyl ether (50ml) and cooled to 0°C under a nitrogen atmosphere. Water (0.05ml, 2.75mmol) was added, followed by lithium borohydride (0.054g, 2.5mmol). The reaction was stirred at 0°C for another 5 0.75 hours and quenched by addition of 1N NaOH (50ml). The mixture was extracted with ethyl acetate (2 x 100ml), the organic solutions washed with brine, dried (MgSO_4), filtered and evaporated in vacuo. The residue was purified by chromatography on silica gel eluting with 20% ethyl acetate/hexane to obtain the title compound as a white foam: ^1H NMR (250MHz, 10 CDCl_3) δ 7.68 (1H, s), 7.44 (2H, s), 7.15-7.34 (5H, m), 4.23 (1H, dd, $J=3\text{Hz}$), 3.68 (2H, m), 3.44 (2H, br d, $J=7\text{Hz}$), 3.30 (2H, dd, $J=7\text{Hz}$), 2.96 (2H, m), 2.14 (2H, m), 1.74 (2H, m), 1.32 (9H, s).

15 d) (+)-4-Phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)methyl]piperidine Hydrochloride

The compound of step (c) above (1.15g) was dissolved in ethereal hydrogen chloride for 24 hours. The solvent was removed under reduced pressure to afford the title compound: ^1H NMR (360MHz, d_6 -DMSO) δ 1.94-2.20 (4H, m), 2.6 - 2.8 (2H, m), 3.0-3.25 (2H, m), 3.29 (2H, s), 4.40 (2H, m), 4.80 (1H, t, $J=10.5\text{Hz}$), 7.10-7.30 (5H, m), 7.60 (2H, s), 7.95 (1H, s).

EXAMPLE 15

(-)-4-Phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)methyl]piperidine Hydrochloride

25 Prepared by the methods of Examples 14(c) and 14(d) using the compound of Example 14(b), diastereomer A.

EXAMPLE 16

(+)-5-[4-Phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)methyl]piperidin-1-ylmethyl]-2,4-dihydro-[1,2,4]-triazol-3-one

a) N-Methoxycarbonyl chloromethyl imidrazone

5 Sodium methoxide (400mg) was added to a stirred solution of chloroacetonitrile (20g) in dry methanol (120ml). The resulting solution was stirred for 1 hour at room temperature, and then neutralised by the addition of acetic acid. Methyl carbazole (23.6g) was then added and stirring continued for 1 hour. The solvent was then removed under reduced pressure and the 10 residue taken up in ethyl acetate, washed with water and the organic layers separated and dried over $MgSO_4$. Filtration and removal of solvent afforded a white solid. Recrystallisation from isopropanol afforded the title compound as white needles, $mp = 45\text{-}49^\circ C$; 1H NMR(360MHz, $CDCl_3$) δ 1.3 (3H, s), 4.00 (2H, s), 5.5 (2H, br s), 8.8 (1H, br s).

15

b) (+)-5-[4-Phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)methyl]piperidin-1-ylmethyl]-2,4-dihydro-[1,2,4]-triazol-3-one

20 N-Methoxycarbonyl chloromethyl imidrazone (356mg) was added to a stirred suspension of the compound of Example 14 (961mg) and K_2CO_3 (1.19g) in dry dimethylformamide at $0^\circ C$. The resulting solution was warmed to room temperature and stirred for two hours, then filtered through celite. The clear filtrate was then warmed to $150^\circ C$ for 3 hours, cooled to room temperature, diluted with water and extracted into diethyl ether. The organic layers were separated and dried over $MgSO_4$, filtered and the solvent removed under 25 reduced pressure. The product was purified by chromatography on silica gel (10% methanol/dichloromethane) to give the title compound as a white solid. 1H NMR (360MHz, $CDCl_3$) δ 2.22-2.31 (6H, m), 2.78 (2H, m), 3.22 (1H, d, $J=11.0\text{Hz}$), 3.28 (1H, d, $J=11.0\text{Hz}$), 3.39 (2H, s), 3.56 (2H, m), 4.37 (1H, t,

$J=4.0\text{Hz}$), 7.20-7.30 (5H, m), 7.58 (2H, s), 7.75 (1H, s); MS (Cl^+) 545 [M+1]⁺; $[\alpha]_D^{20} = +42.8^\circ\text{C}$ (c = 1 dichloromethane).

EXAMPLE 17

5 (+)-4-Phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)methyl]-
1-(2-(pyrrolidinyl)acetamido)piperidine Hydrochloride

10 1-[3-Dimethylaminopropyl]-3-ethylcarbodiimide hydrochloride (797mg),
hydroxybenzo-triazole trihydrate (475mg) and triethylamine (0.890ml) were
added to a stirred solution of 2-pyrrolidinyl acetic acid hydrochloride (528mg)
15 in dry dimethylformamide at room temperature. After 30 minutes a solution of
the compound of Example 14 (800mg) in dry dimethylformamide was added,
followed by triethylamine (0.590ml). The resulting solution was stirred at
room temperature for 4 hours. The reaction was quenched with water and
extracted into diethyl ether then the organic solution was dried (MgSO_4) and
evaporated to give a yellow oil. The residue was purified by chromatography
20 on grade 3 neutral alumina (1% methanol/dichloromethane) then treated with
ethereal hydrogen chloride to afford the title compound, mp = 106-108°C;
Analysis Calcd. for $\text{C}_{28}\text{H}_{32}\text{F}_6\text{N}_2\text{O}_3\text{HCl} \cdot 0.5\text{H}_2\text{O}$: C, 55.68; H, 5.67; N, 4.64.
Found: C, 55.87; H, 5.65; N, 4.51%. ^1H NMR of free base (360MHz, CDCl_3),
25 δ 1.76 (4H, m), 1.80-1.86 (2H, m), 2.30 (2H, m), 2.55 (4H, m), 2.99 (2H, m),
3.40 (2H, s), 3.51 (2H, s), 3.56 (2H, m), 3.84 (2H, m), 4.30 (1H, t, $J=10\text{Hz}$),
7.20-7.38 (5H, m), 7.67 (1H, s), 7.77 (1H, s), 7.94 (1H, s). MS (Cl^+) 559
[M+1]⁺.

25

EXAMPLE 18

(+)-4-Phenyl-4-[(1-(3-fluoro-5-trifluoromethylphenyl)-2-hydroxyethoxy)methyl]piperidine Hydrochloride

Prepared by the method of Examples 9 and 14 using (3-fluoro-5-trifluoromethylphenyl)acetic acid. ^1H NMR (360MHz, $d_6\text{-DMSO}$) δ 2.04-2.29

(4H, m), 2.67-2.80 (2H, m), 3.18-3.27 (2H, m), 3.37 (2H, s), 4.34 (1H, t, J=4.5Hz), 7.06-7.51 (8H, m).

EXAMPLE 19

5 (+)-5-[4-Phenyl-4-[(1-(3-fluoro-5-trifluoromethylphenyl)-2-hydroxyethoxy)methyl]piperidin-1-ylmethyl]-2,4-dihydro-[1,2,4]-triazol-3-one

Prepared by the method of Example 16 from the compound of Example 18.

¹H NMR (360MHz, CDCl₃) δ 2.17-2.31 (6H, m), 2.78 (2H, m), 3.19 (1H, d, J=10Hz), 3.32 (1H, d, J=10Hz), 3.39 (2H, s), 3.51 (2H, m), 4.30 (1H, t, J=4.0Hz), 6.97-7.34 (8H, m).

EXAMPLE 20

(+)-4-Phenyl-4-[(1-(3-fluoro-5-trifluoromethylphenyl)-2-hydroxyethoxy)methyl]-1-(2-(pyrrolidinyl)acetamido)piperidine Hydrochloride

15 Prepared by the method of Example 17 from the compound of Example 18.

¹H NMR of free base (360MHz, CDCl₃) δ 1.79 (6H, m), 2.20 (2H, m), 2.53 (4H, m), 2.90 (2H, m), 3.22 (2H, m), 3.32-3.42 (4H, m), 3.71 (2H, m), 4.15 (1H, t, J=3.0Hz), 6.80-7.30 (8H, m).

20

EXAMPLE 21

4-Phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-(3-methylureido)ethoxy)methyl]piperidine Hydrochloride

Methyl isocyanate (33μl, 0.56mM) was added to a solution of the compound of Example 13 (300mg, 0.56mM) in dichloromethane (5ml). The reaction was stirred at room temperature for 16h. Dichloromethane (10ml) was added and the solution was washed with water (2 x 20ml) and dried over sodium sulphate. Removal of the solvent *in vacuo* left an oil which was chromatographed on silica eluting with 50% ethyl acetate/petrol to give a

white solid. This was taken up in diethyl ether (5ml) and treated with ethereal HCl (5ml). The solution was left to stand for 16h and the solvent was removed to give the title compound as a white foam. MS (Cl⁺) 504 [M+H]⁺. Analysis Calcd. for C₂₄H₂₇N₃O₂F₆·HCl·H₂O: C, 51.66; H, 5.42; N, 7.53; 5 Found: C, 51.58; H, 5.30; N, 7.16%.

EXAMPLE 22

4-Phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-(acetamido)ethoxy)methyl]piperidine Hydrochloride

10 Acetic anhydride (53μl, 0.56mM) was added to a solution of the compound of Example 13 (300mg, 0.56mM) in dichloromethane (5ml) containing N,N-dimethylaminopyridine (69mg, 0.56mM). The reaction was stirred for 16h, and purified as for Example 21 to give the title compound as a white crystalline solid. m.p. 138-140°C, MS (Cl⁺) 489 [M+H]⁺.

15

EXAMPLE 23

4-Phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-(methansulphonamido)ethoxy)methyl]piperidine Hydrochloride

20 Triethylamine (78μl, 0.56mM) was added to a solution of the compound of Example 13 (300mg, 0.56mM) in dichloromethane (5ml). Methanesulphonyl chloride (43μl, 0.56mM) was added and the solution was stirred for 16h at room temperature. Dichloromethane (10ml) was added and the solution was washed with water (2 x 20ml) and dried over sodium sulphate. Removal of the solvent left an oil which was purified and treated with ethereal HCl as in Example 21, giving the title compound as a white foam (50mg). MS (Cl⁺) 525 [M+H]⁺. ¹H NMR (360MHz, d₆-DMSO) δ 1.98-2.24 (4H, m), 2.70-2.90 (2H, m), 2.79 (3H, s), 3.10-3.42 (6H, m), 3.54-3.59 (1H, m), 4.51-4.59 (1H, m), 7.01-7.06 (1H, m), 7.24-7.45 (4H, m), 7.67 (2H, s), 7.99 (1H, s), 8.49 (1H, br s).

EXAMPLE 244-Phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-(carbomethoxymethoxy)ethoxy)methyl]piperidine Hydrochloride

Prepared from the compound of Example 1(d) by the method of Example 2, using methyl bromoacetate in place of methyl iodide. ^1H NMR (360MHz, d_6 -DMSO) δ 2.00-2.12 (2H, m), 2.24-2.35 (2H, m), 2.62-2.77 (2H, m), 3.17 (2H, br m), 3.29 (1H, d, J =6.0Hz), 3.62 (3H, s + m), 4.01 (2H, s), 4.08 (1H, t, J =6.0Hz), 7.24-7.41 (5H, m), 7.68 (2H, s), 7.97 (1H, s). MS (EI $^+$) 520 (M+H $^+$).

10

EXAMPLE 254-(4-Fluorophenyl)-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)methyl]-1-(2-(1-pyrrolidinyl)acetamido)piperidine Hydrochloride

15

a) Methyl 4-fluorophenylacetate

4-Fluorophenyl acetic acid (25g) was dissolved in anhydrous methanol, stirred under nitrogen and cooled in an ice/methanol bath. Dry HCl gas was bubbled through the reaction for 1hr. The methanol was removed by rotary evaporator and the residue was dispersed between aqueous sodium hydrogen carbonate and dichloromethane. The organic layer was washed with brine, dried (MgSO_4) and concentrated to afford the title compound as a clear oil (24.4g). ^1H NMR (360MHz, CDCl_3) δ 3.61 (2H, s), 3.70 (3H, s), 6.97-7.06 (2H, m), 7.20-7.27 (2H, m). MS Cl^+ 169 [M+H] $^+$.

20

b) 4-(4-Fluorophenyl)-4-carbomethoxy-1-methylpiperidine

Methyl 4-fluorophenylacetate (24.4g) was dissolved in dry dimethyl sulphoxide (150ml) and added dropwise to sodium hydride (15.7g of an 80% dispersion in oil) under nitrogen. After 20 minutes mechlorethamine hydrochloride (24g) in dry dimethyl sulphoxide (125ml) was added over a

period of 20 minutes. The reaction was poured onto ice (200ml) and left overnight. The mixture was extracted with diethyl ether (50 x 250ml) and the combined organic solutions were extracted with 5N HCl (100ml). The aqueous solution was treated with potassium carbonate and extracted with ethyl acetate (3 x 250ml). The combined organic extracts were dried (MgSO₄) and concentrated *in vacuo* to afford a brown oil. The oil was purified by flash chromatography eluting with ethyl acetate graduated to 8% methanol in ethyl acetate, to afford the title compound (9.5g). ¹H NMR (360MHz, CDCl₃) δ 1.9-2.03 (2H, m), 2.07-2.19 (2H, m), 2.27 (3H, s), 2.51-2.62 (2H, m), 2.72-2.86 (2H, m), 3.65 (3H, s), 6.98-7.06 (2H, m), 7.27-7.39 (2H, m). MS (Cl⁺) 224 [M+H]⁺.

c) 4-(4-Fluorophenyl)-4-hydroxymethyl-1-*tert*-butoxycarbonylpiperidine
4-(4-Fluorophenyl-4-carbomethoxy-1-methylpiperidine (19.2g) in 1,2-dichloroethane (400ml) at 5°C was treated with chloroethylchloroformate (23.4ml) for 15 minutes. The solution was heated under reflux for 12 hours then cooled and concentrated under reduced pressure. The residual oil was dissolved in methanol (600ml) and heated under reflux for 3 hours then cooled and concentrated. The residue in tetrahydrofuran (225ml) at 0°C was treated with lithium aluminium hydride (108.5ml of a 1.0M solution in tetrahydrofuran) and, after 10 minutes, the solution was heated under reflux for 3 hours. The reaction was cooled then quenched by addition of water (4.1ml), 15% sodium hydroxide (4.1ml) and water (12.1ml). Di-*tert*-butyl dicarbonate (18.9g) in dichloromethane (250ml) was added and the mixture was stirred for 16 hours then filtered through sodium sulphate. The solution was concentrated and the residue purified by chromatography on silica gel eluting with hexane/ethyl acetate (3:2) to give the title compound as a white solid, MS (Cl⁺) 310 [M+H]⁺.

d) 4-(4-Fluorophenyl)-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)methyl]-1-(2-(1-pyrrolidinyl)acetamido)piperidine hydrochloride

Prepared from 4-(4-fluorophenyl)-4-hydroxymethyl-1-*tert*-butoxycarbonyl piperidine using the methods described in Examples 1 and 8. m.p. 128-131°C; Analysis Calcd. for C₁₈H₃₁F₇N₂O₃. HCl. H₂O: C, 53.29; H, 5.43; N, 4.44; Found: C, 53.41; H, 5.47; N, 4.30%.

EXAMPLE 26

10 (+)-4-(4-Fluorophenyl)-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)methyl]-1-(2-(1-pyrrolidinyl)acetamido)piperidine Hydrochloride.

Prepared from 4-(4-fluorophenyl)-4-hydroxymethyl-1-*tert*-butoxycarbonylpiperidine by the methods detailed in Examples 9, 14 and 17. m.p. 134-136°C; Analysis Calcd. for C₁₈H₃₁F₆N₂O₃. HCl: C, 54.86; H, 5.26; N, 4.56; Found: C, 54.48; H, 4.96; N, 4.72%.

EXAMPLE 27

20 4-Phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-1-hydroxymethyl-2-hydroxyethoxy)methyl]piperidine Hydrochloride

(a) 1-*tert*-Butoxycarbonyl-4-phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-benzyloxy-1-methoxycarbonylethoxy)methyl]piperidine

Diisopropylamine (0.63ml, 4.5mmol) was added to degassed anhydrous tetrahydrofuran and the flask cooled to 0°C. n-Butyl lithium (1.6M in hexanes, 2.8ml, 4.5mmol) was added dropwise, the solution stirred for a further 10 minutes and cooled to -78°C. The compound of Example 9(c) (2.0g, 3.5mmol) was azeotroped with toluene and dissolved in anhydrous tetrahydrofuran (15ml). The solution was degassed with nitrogen for 5

minutes and added dropwise to the freshly prepared lithium diisopropylamine and stirred for a further 30 minutes. The anion was then quenched with benzyloxychloromethyl ether (0.63ml, 4.5mmol), stirred for a further 10 minutes and warmed to 0°C for a further 1h. Saturated aqueous ammonium chloride solution (50ml) was added and the product extracted into ethyl acetate (2 x 75ml). The combined organic layers were dried over (MgSO₄) and removed *in vacuo*. The residue was chromatographed on silica eluting with 15% ethyl acetate/petroleum ether to give a colourless oil. ¹H NMR (CDCl₃) δ 7.76 (1H, s), 7.73 (2H, s), 7.23-7.37 (8H, m), 7.09 (2H, m), 4.40 (2H, dd), 3.82 (2H, dd), 3.65 (3H, s), 3.73 (2H, dt), 3.56 (1H, d), 3.40 (1H, d), 3.09 (br t, 2H), 2.21 (2H, br m), 1.89 (2H, m), 1.44 (9H, s).

b) 4-Phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-1-hydroxymethyl-2-hydroxyethoxy)methyl]piperidine Hydrochloride

15 The oil from step (a) above was dissolved in anhydrous tetrahydrofuran (50ml) and lithium borohydride (0.140g, 6.5mmol) was added. The reaction was stirred at 25°C for 30 minutes and quenched with saturated aqueous ammonium chloride solution (75ml) and extracted into ethyl acetate (75ml). The organic layer was dried over (MgSO₄) and removed *in vacuo*. The residue was dissolved in ethanol (15ml) and hydrogenated at 50psi over Pd(OH)₂ (0.150g) for 16h. The catalyst was filtered and the solvent evaporated. The residue was chromatographed on silica eluting with ethyl acetate. The oil obtained was treated with ethereal HCl and left standing for 16h. The solid formed was filtered off and washed with ether to obtain the title compound. ¹H NMR (DMSO-d₆) δ 7.99 (1H, s), 7.75 (2H, s), 7.48 (4H, m), 7.35 (1H, m), 3.85 (4H, s), 3.47 (2H, s), 3.33 (2H, br d), 2.97 (2H, br t), 2.56 (2H, br d), 2.10 (2H, br t). MS (Cl⁺) 478 [M+H]⁺.

5-[4-Phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-1-hydroxymethyl-2-hydroxyethoxy)methyl)piperidin-1-ylmethyl]-2,4-dihydro-[1,2,4]-triazol-3-one

Prepared from the compound of Example 27, by the method described in Example 7, m.p. 148-150°C, MS (Cl⁺) 575 [M+H]⁺.

5

EXAMPLE 29

4-Phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)cyclopropyloxy)methyl]piperidine Hydrochloride

The compound of Example 1(c) (0.500g, 0.922mmol) was dissolved in anhydrous ether (10ml) and diethylzinc (1.0M solution in hexanes, 1.84ml, 1.84mmol) was added. The solution was cooled to 0°C and diiodomethane (0.15ml, 1.84mmol) was added. The reaction was diluted with ethyl acetate (50ml) and washed with saturated aqueous ammonium chloride solution.

The organic layer was dried over (MgSO₄) and evaporated. The residue was purified by chromatography on silica eluting with 5% ethyl acetate/hexanes→10% ethyl acetate/hexanes. The product obtained was left standing in HCl/ether for 16h. The solvent was removed *in vacuo* and the title compound suspended in ether and filtered. ¹H NMR (DMSO-d₆) δ 7.90 (1H, s), 7.50 (2H, s), 7.29-7.40 (5H, m), 3.36 (2H, s), 3.17 (2H, m), 2.74 (2H, m), 2.30 (2H, m), 2.01 (2H, m), 1.13 (4H, m). MS (Cl⁺) 444 [M+H]⁺.

EXAMPLE 30

4-Phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)cyclopropyloxy)methyl]-1-(2-(1-pyrrolidinyl)acetamido)piperidine Hydrochloride

Prepared from the compound of Example 29 by the method of Example 8; m.p. 158-160°C. ¹H NMR (DMSO-d₆) δ 7.90 (1H, s), 7.52 (2H, s), 7.34-7.51 (4H, m), 7.28 (1H, m), 4.32 (2H, dd), 3.84 (1H, m), 3.38 (7H, m), 3.04 (2H), 2.16 (2H), 1.78-1.99 (m, 6H).

EXAMPLE 314-Phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-1-methyl-2-hydroxyethoxy)methyl]piperidine Hydrochloride5 (a) tert-Butoxycarbonyl-4-phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-1-methyl-2-methoxycarbonylethoxy)methyl]piperidine

Diisopropylamine (0.37ml, 2.80mmol) was added to de-gassed tetrahydrofuran (10ml) and the solution cooled to 0°C. n-Butyl lithium (1.6M in hexanes, 1.7ml, 2.80mmol) was added and the reaction stirred for 10 minutes. The lithium diisopropylamine solution was cooled to -78°C and the compound of Example 9(c) (1.1g, 0.191mmol, as a solution in de-gassed tetrahydrofuran) added dropwise. The yellow anion was stirred for 40 minutes before addition of methyl iodide (0.17ml, 0.280mmol) dropwise. The reaction was stirred at -78°C for 1h, and quenched with aqueous ammonium chloride and allowed to warm to room temperature. The product was extracted into ethyl acetate (50ml) and the organic layer dried (MgSO_4) and evaporated. The residue was chromatographed on silica eluting with 15% ethyl acetate/hexanes to give the title compound as a colourless oil. ^1H NMR (CDCl_3) δ 7.76 (3H, s), 7.35 (4H, m), 7.26 (1H, m), 3.80 (2H, m), 3.76 (3H, s), 3.47 (1H, d), 3.36 (1H, d), 3.05 (2H, m), 2.20-2.37 (2H, m), 1.86-1.91 (2H, m), 1.58 (3H, s), 1.44 (9H, s).

20 (b) 4-Phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-1-methyl-2-hydroxyethoxy)methyl]piperidine Hydrochloride

25 The oil from step (a) above (0.66g) was dissolved in tetrahydrofuran (8ml) and lithium borohydride (0.082g, 3.3mmol) added and the reaction stirred for 3h. The reaction mixture was concentrated in vacuo and saturated aqueous ammonium chloride added carefully. The product was extracted into ethyl acetate (2 x 25ml), the combined organic layers dried (MgSO_4) and

evaporated. The residue was dissolved in ethereal HCl and after 10 minutes at 25°C, the solvent removed in vacuo. The resulting white solid was filtered and washed with ether to give the title compound. ^1H NMR (DMSO-d₆) δ 7.82 (1H, s), 7.75 (2H, s), 7.38-7.45 (4H, m), 7.32 (1H, m), 3.57 (2H, s), 3.46 (1H, d), 3.30 (2H, m (under H₂O peak)), 3.20 (1H, d), 2.94 (2H, m), 2.55 (2H, m), 2.15 (2H, m), 1.48 (3H, s). MS (Cl⁺) 462 [M+H]⁺.

EXAMPLE 32

5-[4-Phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-1-methyl-2-hydroxyethoxy)methyl]piperidin-1-yl)methyl]-2,4-dihydro-[1,2,4]-triazol-3-one

10

Prepared by the method described in Example 7 from the compound of Example 31. m.p. 142-144°C. MS (Cl⁺) 559 [M+H]⁺.

EXAMPLE 33

4-Phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-1-methyl-2-hydroxyethoxy)methyl]-1-(2-(1-pyrrolidinyl)acetamido)piperidine Hydrochloride


15

Prepared by the method described in Example 8 from the compound of Example 31. ^1H NMR (DMSO-d₆) δ 7.94 (1H, s), 7.73 (2H, d), 7.43 (2H, d), 7.36 (2H, t), 7.26 (1H, t), 4.79 (1H, dd), 4.39 (1H, d), 4.25 (1H, d), 3.88 (1H, m), 3.47 (6H, m), 3.22 (2H, m), 3.07 (2H, m), 2.17 (2H, m), 1.92 (6H, m), 1.39 (3H, s). MS (Cl⁺) 573 [M+H]⁺.

20

CLAIMS:

1. A compound of the formula (I) or a pharmaceutically acceptable
 5 salt thereof:



wherein

10 A¹ and A² each independently represent hydrogen or C₁-4alkyl;
 m is 2, 3 or 4;
 n is zero, 1 or 2 when m is 2 or 3 and n is zero or 1 when m is 4;
 R¹ represents phenyl optionally substituted by 1, 2 or 3 groups
 selected from C₁-6alkyl, C₂-6alkenyl, C₂-6alkynyl, C₃-6cycloalkyl,
 15 C₃-6cycloalkylC₁-4alkyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl,
 -OR^a, -SR^a, -SOR^a, -SO₂R^a, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -COR^a,
 -CO₂R^a or -CONR^aR^b, where R^a and R^b each independently represent H,
 C₁-6alkyl, phenyl or trifluoromethyl;
 R² represents phenyl optionally substituted by 1, 2 or 3 groups
 20 selected from C₁-6alkyl, C₂-6alkenyl, C₂-6alkynyl, C₃-6cycloalkyl,
 C₃-6cycloalkylC₁-4alkyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl,
 -OR^a, -SR^a, -SOR^a, -SO₂R^a, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -CO₂R^a
 or -CONR^aR^b, where R^a and R^b are as previously defined; heteroaryl
 selected from indazolyl, thienyl, furyl, pyridyl, thiazolyl, tetrazolyl and

quinolyl; benzhydryl; or benzyl; wherein each heteroaryl and each phenyl moiety of benzyl and benzhydryl may be substituted by C₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₄alkyl, C₁₋₆alkoxy, halo or trifluoromethyl;

5 R³ represents H, COR⁹, CO₂R¹⁰, COCONR¹⁰R¹¹, COCO₂R¹⁰, SO₂R¹⁵, CONR¹⁰SO₂R¹⁵, C₁₋₆alkyl optionally substituted by a group selected from (CO₂R¹⁰, CONR¹⁰R¹¹, hydroxy, cyano, COR⁹, NR¹⁰R¹¹, C(NO_H)NR¹⁰R¹¹, CONHphenyl(C₁₋₄alkyl), COCO₂R¹⁰, COCONR¹⁰R¹¹, SO₂R¹⁵, CONR¹⁰SO₂R¹⁵ and phenyl optionally substituted by 1, 2 or 3 substituents selected from C₁₋₆alkyl, C₃₋₆cycloalkyl,

10 C₃₋₆cycloalkylC₁₋₄alkyl, C₁₋₆alkoxy, halo and trifluoromethyl), Y-R⁸ or CO-Z-(CH₂)_q-R¹²;

R⁴ represents C₁₋₆alkyl substituted by a hydroxy group, or (CH₂)_pNR¹⁰R¹¹, CO₂R¹⁶, CONR¹⁰R¹¹, (CH₂)_pCO₂R¹⁶, (CH₂)_pCONR¹⁰R¹¹, (CH₂)_pNR¹⁰COR¹⁸, (CH₂)_pNR¹⁰SO₂R¹⁵, (CH₂)_pOR¹⁶, (CH₂)_pOC(O)R¹⁰ or (CH₂)_pO(CH₂)_rCOR¹⁷;

15 R⁵ represents hydrogen or C₁₋₆alkyl optionally substituted by a hydroxy group, or (CH₂)_pNR¹⁰R¹¹, CO₂R¹⁶, CONR¹⁰R¹¹, (CH₂)_pCO₂R¹⁶, (CH₂)_pCONR¹⁰R¹¹, (CH₂)_pNR¹⁰COR¹⁸, (CH₂)_pNR¹⁰SO₂R¹⁵, (CH₂)_pOR¹⁶, (CH₂)_pOC(O)R¹⁰ or (CH₂)_pO(CH₂)_rCOR¹⁷;

20 or R⁴ and R⁵ together with the carbon atom to which they are attached form a C₃₋₆cycloalkyl ring which may be substituted by 1 or 2 groups selected from C₁₋₆alkyl, C₁₋₆alkoxy, hydroxy or C₁₋₆alkyl substituted by hydroxy;

25 R⁶ and R⁷ each independently represent H or C₁₋₆alkyl;

R⁸ represents an optionally substituted aromatic heterocycle;

R⁹ represents H, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₄alkyl, or phenyl;

R¹⁰ and R¹¹ each independently represent H or C₁₋₆alkyl;

R¹² represents NR¹³R¹⁴ or an optionally substituted aromatic or non-aromatic azacyclic or azabicyclic group;

R¹³ and R¹⁴ each independently represent H, C₁₋₆alkyl, phenyl optionally substituted by 1, 2 or 3 groups selected from C₁₋₆alkyl, C₁₋₆alkoxy, halo or trifluoromethyl, or phenylC₁₋₄alkyl optionally substituted in the phenyl ring by 1, 2 or 3 groups selected from C₁₋₆alkyl, C₁₋₆alkoxy, halo or trifluoromethyl;

R¹⁵ represents C₁₋₆alkyl, trifluoromethyl or phenyl optionally substituted by 1, 2 or 3 substituents selected from C₁₋₆alkyl, C₁₋₆alkoxy, halo and trifluoromethyl;

R¹⁶ represents C₁₋₆alkyl;

R¹⁷ represents C₁₋₆alkoxy, amino, C₁₋₄alkylamino or di(C₁₋₄alkyl)amino;

R¹⁸ represents C₁₋₆alkyl, NR¹³R¹⁴ or an optionally substituted aromatic or non-aromatic azacyclic or azabicyclic group;

X represents O or NR¹⁹ where R¹⁹ represents hydrogen or C₁₋₆alkyl;

Y represents a hydrocarbon chain of 1, 2, 3 or 4 carbon atoms which may optionally be substituted by oxo;

Z represents CH₂, O, S or NR¹⁰;

p represents an integer from 1 to 4;

q represents zero or an integer from 1 to 6; and

r represents an integer from 1 to 4.

2. A compound as claimed in claim 1 wherein

A¹ and A² each independently represent hydrogen or C₁₋₄alkyl;

m is 2, 3 or 4;

n is zero, 1 or 2 when m is 2 or 3 and n is zero or 1 when m is 4;

R¹ represents phenyl optionally substituted by 1, 2 or 3 groups selected from C₁-6alkyl, C₂-6alkenyl, C₂-6alkynyl, C₃-6cycloalkyl, C₃-6cycloalkylC₁-4alkyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, -OR^a, -SR^a, -SOR^a, -SO₂R^a, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -COR^a, -CO₂R^a or -CONR^aR^b, where R^a and R^b each independently represent H, C₁-6alkyl, phenyl or trifluoromethyl;

R² represents phenyl optionally substituted by 1, 2 or 3 groups selected from C₁-6alkyl, C₂-6alkenyl, C₂-6alkynyl, C₃-6cycloalkyl, C₃-6cycloalkylC₁-4alkyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, -OR^a, -SR^a, -SOR^a, -SO₂R^a, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -CO₂R^a or -CONR^aR^b, where R^a and R^b are as previously defined; heteroaryl selected from indazolyl, thienyl, furyl, pyridyl, thiazolyl, tetrazolyl and quinolyl; benzhydryl; or benzyl; wherein each heteroaryl and each phenyl moiety of benzyl and benzhydryl may be substituted by C₁-6alkyl, C₃-6cycloalkyl, C₃-6cycloalkylC₁-4alkyl, C₁-6alkoxy, halo or trifluoromethyl;

R³ represents H, COR⁹, CO₂R¹⁰, COCONR¹⁰R¹¹, COCO₂R¹⁰, SO₂R¹⁵, CONR¹⁰SO₂R¹⁵, C₁-6alkyl optionally substituted by a group selected from (CO₂R¹⁰, CONR¹⁰R¹¹, hydroxy, cyano, COR⁹, NR¹⁰R¹¹, C(NOH)NR¹⁰R¹¹, CONHphenyl(C₁-4alkyl), COCO₂R¹⁰, COCONR¹⁰R¹¹, SO₂R¹⁵, CONR¹⁰SO₂R¹⁵ and phenyl optionally substituted by 1, 2 or 3 substituents selected from C₁-6alkyl, C₃-6cycloalkyl, C₃-6cycloalkylC₁-4alkyl, C₁-6alkoxy, halo and trifluoromethyl), Y-R⁸ or CO-Z-(CH₂)_q-R¹²;

R⁴ is C₁-6alkyl substituted by a hydroxy group, or (CH₂)_pNR¹⁰R¹¹, CO₂R¹⁶, CONR¹⁰R¹¹, (CH₂)_pCO₂R¹⁶, (CH₂)_pCONR¹⁰R¹¹, (CH₂)_pNR¹⁰COR¹⁶, (CH₂)_pNHSO₂R¹², (CH₂)_pOR¹⁶, (CH₂)_pOC(O)R¹⁰ or (CH₂)_pO(CH₂)_rCOR¹⁷;

R⁵, R⁶ and R⁷ each independently represent H or C₁-6alkyl;

R⁸ represents an optionally substituted aromatic heterocycle;

R⁹ represents H, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₄alkyl, or phenyl;

R¹⁰ and R¹¹ each independently represent H or C₁₋₆alkyl;

R¹² represents NR¹³R¹⁴ or an optionally substituted aromatic or non-aromatic azacyclic or azabicyclic group;

R¹³ and R¹⁴ each independently represent H, C₁₋₆alkyl, phenyl optionally substituted by one or more of C₁₋₆alkyl, C₁₋₆alkoxy, halo or trifluoromethyl or phenylC₁₋₄alkyl optionally substituted in the phenyl ring by 1, 2 or 3 groups selected from C₁₋₆alkyl, C₁₋₆alkoxy, halo or trifluoromethyl;

R¹⁵ represents C₁₋₆alkyl, trifluoromethyl or phenyl optionally substituted by 1, 2 or 3 substituents selected from C₁₋₆alkyl, C₁₋₆alkoxy, halo and trifluoromethyl;

R¹⁶ represents C₁₋₆alkyl;

R¹⁷ represents C₁₋₆alkoxy, amino, C₁₋₄alkylamino or di(C₁₋₄alkyl)amino;

Y represents a hydrocarbon chain of 1,2,3 or 4 carbon atoms which may optionally be substituted by oxo;

Z represents CH₂, O, S or NR¹⁰;

p represents 1 to 4;

q represents zero, 1, 2, 3, 4, 5 or 6;

r represents 1 to 4;

X represents O or NR¹⁹ where R¹⁹ represents hydrogen or C₁₋₆alkyl; or a pharmaceutically acceptable salt thereof.

25 3. A compound as claimed in claim 1 wherein

A¹ and A² each independently represent hydrogen or C₁₋₄ alkyl;

m is 2, 3 or 4;

n is zero, 1 or 2 when m is 2 or 3 and n is zero or 1 when m is 4;

R¹ represents phenyl optionally substituted by 1, 2 or 3 groups selected from C₁-6alkyl, C₂-6alkenyl, C₂-6alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, -OR^a, -SR^a, -SOR^a, -SO₂R^a, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -COR^a, -CO₂R^a or -CONR^aR^b, where R^a and R^b each independently represent H, C₁-6alkyl, phenyl or trifluoromethyl;

R² represents phenyl optionally substituted by 1, 2 or 3 groups selected from C₁-6alkyl, C₂-6alkenyl, C₂-6alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, -OR^a, -SR^a, -SOR^a, -SO₂R^a, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -CO₂R^a or -CONR^aR^b, where R^a and R^b are as previously defined; heteroaryl selected from indazolyl, thienyl, furyl, pyridyl, thiazolyl, tetrazolyl and quinolyl; benzhydryl; or benzyl; wherein each heteroaryl and each phenyl moiety of benzyl and benzhydryl may be substituted by C₁-6alkyl, C₁-6alkoxy, halo or trifluoromethyl;

R³ represents H, COR⁹, CO₂R¹⁰, COCONR¹⁰R¹¹, COCO₂R¹⁰, SO₂R¹⁵, CONR¹⁰SO₂R¹⁵, C₁-6alkyl optionally substituted by a group selected from (CO₂R¹⁰, CONR¹⁰R¹¹, hydroxy, cyano, COR⁹, NR¹⁰R¹¹, C(NO₂)NR¹⁰R¹¹, CONHphenyl(C₁-4alkyl), COCO₂R¹⁰, COCONR¹⁰R¹¹, SO₂R¹⁵, CONR¹⁰SO₂R¹⁵ and phenyl optionally substituted by one or more substituents selected from C₁-6alkyl, C₁-6alkoxy, halo and trifluoromethyl), Y-R⁸ or CO-Z-(CH₂)_q-R¹²;

R⁴ is C₁-6alkyl substituted by a hydroxy group, or (CH₂)_pNR¹⁰R¹¹, CO₂R¹⁶, CONR¹⁰R¹¹, (CH₂)_pCO₂R¹⁶, (CH₂)_pCONR¹⁰R¹¹, (CH₂)_pNR¹⁰COR¹⁶, (CH₂)_pNHSO₂R¹², (CH₂)_pOR¹⁶, (CH₂)_pOC(O)R¹⁰ or (CH₂)_pO(CH₂)_rCOR¹⁷;

R⁵, R⁶ and R⁷ each independently represent H or C₁-6alkyl;

R⁸ represents an optionally substituted aromatic heterocycle;

R⁹ represents H, C₁-6alkyl or phenyl;

R¹⁰ and R¹¹ each independently represent H or C₁-6alkyl;

R¹² represents NR¹³R¹⁴ or an optionally substituted aromatic or non-aromatic azacyclic or azabicyclic group;

R¹³ and R¹⁴ each independently represent H, C₁-₆alkyl, phenyl optionally substituted by one or more of C₁-₆alkyl, C₁-₆alkoxy, halo or trifluoromethyl or phenylC₁-₄alkyl optionally substituted in the phenyl ring by one or more of C₁-₆alkyl, C₁-₆alkoxy, halo or trifluoromethyl;

R¹⁵ represents C₁-₆alkyl, trifluoromethyl or phenyl optionally substituted by one or more substituents selected from C₁-₆alkyl, C₁-₆alkoxy, halo and trifluoromethyl;

R¹⁶ represents C₁-₆alkyl;

R¹⁷ represents C₁-₆alkoxy, amino, C₁-₄alkylamino or di(C₁-₄alkyl)amino;

Y represents a hydrocarbon chain of 1,2,3 or 4 carbon atoms which may optionally be substituted by oxo;

Z represents CH₂, O, S or NR¹⁰;

p represents 1 to 4;


q represents zero, 1, 2, 3, 4, 5 or 6;

r represents 1 to 4;

X represents O or NR¹⁹ where R¹⁹ represents hydrogen or C₁-₆alkyl.

or a pharmaceutically acceptable salt thereof.

4. A compound as claimed in claim 1 of formula (Ia):



wherein

R³ and X are as defined in claim 1;

R²⁰ and R²¹ independently represent H, C₁-6alkyl, C₂-6alkenyl, C₂-6alkynyl, C₃-6cycloalkyl, C₃-6cycloalkylC₁-4alkyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a, SR^a, SOR^a, SO₂R^a, NR^aR^b, NR^aCOR^b, NR^aCO₂R^b, COR^a, CO₂R^a or CONR^aR^b, where R^a and R^b are as previously defined in claim 1;

R²² represents H or halo;

10 R²³ is C₁-6alkyl substituted by a hydroxy group; and

R²⁴ is H or methyl;

or a pharmaceutically acceptable salt thereof.

5. A compound selected from:

15 4-phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)methyl)piperidine;

4-phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-2-methoxyethoxy)methyl)piperidine;

4-phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-2-ethoxyethoxy)methyl)piperidine;

20 4-phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-2-cyclopropylmethoxyethoxy)methyl)piperidine;

4-phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-2-methoxycarbonylmethoxyethoxy)methyl)piperidine;

25 4-phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-2-acetoxyethoxy)methyl)piperidine;

5[(4-phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)methyl)piperidin-1-yl)methyl]-2,4-dihydro-[1,2,4]-triazol-3-one;

4-phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)methyl)-1-(2-(1-pyrrolidinyl)acetamido)piperidine;

5 methyl 2-(4-phenylpiperidin-4-yl)methoxy-2-(3,5-bis(trifluoromethyl)phenyl)acetate;

10 isopropyl 2-(4-phenylpiperidin-4-yl)methoxy-2-(3,5-bis(trifluoromethyl)phenyl)acetate;

15 4-phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropyloxy)methyl]piperidine;

20 2-(4-phenylpiperidin-4-yl)methoxy-2-(3,5-bis(trifluoromethyl)phenyl)acetamide;

25 4-phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-aminoethoxy)methyl]piperidine;

30 4-phenyl-4-[(1-(3-fluoro-5-trifluoromethylphenyl)-2-hydroxyethoxy)methyl]piperidine;

35 5-[4-phenyl-4-[(1-(3-fluoro-5-trifluoromethylphenyl)-2-hydroxyethoxy)methyl]piperidin-1-ylmethyl]-2,4-dihydro-[1,2,4]-triazol-3-one;

40 4-phenyl-4-[(1-(3-fluoro-5-trifluoromethylphenyl)-2-hydroxyethoxy)methyl]-1-(2-(pyrrolidinyl)acetamido)piperidine;

45 4-phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-(3-methylureido)ethoxy)methyl]piperidine;

50 4-phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-acetamido)methyl]piperidine;

55 4-phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-methansulphonamido)methyl]piperidine;

60 4-phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-(carbomethoxymethoxy)ethoxy)methyl]piperidine;

65 4-(4-fluorophenyl)-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)methyl]-1-(2-(1-pyrrolidinyl)acetamido)piperidine;

70 (+)-4-(4-fluorophenyl)-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)methyl]-1-(2-(1-pyrrolidinyl)acetamido)piperidine;

4-phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-1-hydroxymethyl-2-hydroxyethoxy)methyl]piperidine;

5-[4-phenyl-4-((1-(3,5-bis(trifluoromethyl)phenyl)-1-hydroxymethyl-2-hydroxyethoxy)methyl)piperidin-1-ylmethyl]-2,4-dihydro-[1,2,4]-triazol-3-one;

5 4-phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)cyclopropoxy)methyl]piperidine;

4-phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)cyclopropoxy)methyl]-1-(2-(1-pyrrolidinyl)acetamido)piperidine;

10 4-phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-1-methyl-2-hydroxyethoxy)methyl]piperidine;

5-[4-phenyl-4-[(1-(3,5-bis(trifluoromethyl)phenyl)-1-methyl-2-hydroxyethoxy)methyl]piperidin-1-yl)methyl]-2,4-dihydro-[1,2,4]-triazol-3-one;

or a pharmaceutically acceptable acid addition salt thereof.

15 6. A compound as claimed in any preceding claim for use in therapy.

7. A pharmaceutical composition comprising a compound as claimed in any one of Claims 1 to 5 in association with a pharmaceutically acceptable carrier or excipient.

20 25 8. A method for the treatment or prevention of physiological disorders associated with an excess of tachykinins, which method comprises administration to a patient in need thereof of a tachykinin reducing amount of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

9. A method according to Claim 8 for the treatment or prevention of pain or inflammation.

10. A method according to Claim 8 for the treatment or prevention
5 of migraine.

11. A method according to Claim 8 for the treatment or prevention of emesis.

10 12. The use of a compound as claimed in Claim 1 for the manufacture of a medicament for the treatment of a physiological disorder associated with an excess of tachykinins.


15 13. The use of a compound as claimed in claim 1 for the manufacture of a medicament for the treatment of pain or inflammation.

14. The use of a compound as claimed in Claim 1 for the manufacture of a medicament for the treatment of migraine.

20 15. The use of a compound as claimed in Claim 1 for the manufacture of a medicament for the treatment of emesis.

16. A process for the preparation of a compound of formula (I) which comprises:

25 (A) reacting a compound of the formula (II) with a compound of the formula (III)



wherein A¹, A², R¹, R², R³, R⁴, R⁵, R⁶, R⁷, m and n are as defined in claim 1, or a protected derivative thereof; and one of R³⁰ and R³¹ represents a leaving group and the other represents a OH or NR¹⁹ group where R¹⁹ is as defined in claim 1; in the presence of base followed by deprotection if required; or

(B) by interconversion of a compound of formula (I) into another compound of formula (I);

10 each process being followed, where necessary, by the removal of any protecting group where present;

and when the compound of formula (I) is obtained as a mixture of enantiomers or diastereoisomers, optionally resolving the mixture to obtain the desired enantiomer;

15 and/or, if desired, converting the resultant compound of formula (I) or a salt thereof into a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

Int. Application No
GB 95/00057

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D211/22 A61K31/445 C07D401/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO,A,94 13639 (MERCK SHARP & DOHME) 23 June 1994 see claim 1 ---	1-16
P, X	WO,A,94 10165 (MERCK SHARP & DOHME) 11 May 1994 see claim 1 ---	1-16
P, A	WO,A,94 19323 (MERCK SHARP & DOHME) 1 September 1994 see claim 1 ---	1-16
A	EP,A,0 474 561 (SANOFI) 11 March 1992 see claim 1 ---	1-16
A	WO,A,93 21181 (MERCK SHARP & DOHME) 28 October 1993 see claim 1 ---	1-16
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *'A' document defining the general state of the art which is not considered to be of particular relevance
- *'E' earlier document but published on or after the international filing date
- *'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *'O' document referring to an oral disclosure, use, exhibition or other means
- *'P' document published prior to the international filing date but later than the priority date claimed

*'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

*'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

*'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

*'&' document member of the same patent family

Date of the actual completion of the international search

20 April 1995

Date of mailing of the international search report

- 2. 05. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentiaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Gettins, M

INTERNATIONAL SEARCH REPORT

Int. Application No
PCT/GB 95/00057

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 285 032 (A/S FERROSAN) 5 October 1988 see claim 1 -----	1

1

INTERNATIONAL SEARCH REPORT

Int'l. Application No.
PCT/GB 95/00057

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9413639	23-06-94	AU-B-	5657394	04-07-94
WO-A-9410165	11-05-94	AU-B-	5342994	24-05-94
WO-A-9419323	01-09-94	AU-B-	6109394	14-09-94
EP-A-474561	11-03-92	FR-A-	2666335	06-03-92
		FR-A-	2678267	31-12-92
		AU-B-	657272	09-03-95
		AU-A-	8354291	12-03-92
		CA-A-	2050639	06-03-92
		JP-A-	4261155	17-09-92
		NZ-A-	239661	27-06-94
		US-A-	5350852	27-09-94
		US-A-	5236921	17-08-93
WO-A-9321181	28-10-93	AU-B-	4076593	18-11-93
		CA-A-	2133077	28-10-93
		EP-A-	0636130	01-02-95
		AU-B-	4713993	14-02-94
		CA-A-	2138650	03-02-94
		WO-A-	9402461	03-02-94
EP-A-285032	05-10-88	AU-A-	1379488	29-09-88
		JP-A-	63258456	25-10-88
		US-A-	4845095	04-07-89
		ZA-A-	8801799	05-09-88

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)